Introduction {#s1}
============

Development of the mammalian binocular visual system requires topographic synaptic connections of retinal ganglion cell (RGC) axons to neurons on the lateral geniculate nucleus and superior colliculus of the brain ([@bib25]). To access their synaptic targets, RGC axons exit from the retina and grow in selective directions by recognizing guidance cues expressed in optic pathway structures, including the optic disc (OD), optic stalk (OS), optic chiasm (OC), and optic tract (OT) ([@bib32]). RGC axon guidance cues include cell surface ligands such as semaphorins in the OS and ephrinB2 in the OC, and soluble factors such as netrin-1 in the OD and Slit1 in areas surrounding the OC ([@bib11]). Ultimately, only about 3% of mouse RGC axons, which originate from the ventral and temporal part of the retina, are linked to targets on the same side of the brain, whereas a majority of RGC axons are connected to those on the opposite side after crossing the midline at the OC, located at the ventral-medial hypothalamic (vHT) area.

Subsets of vHT cells therefore express molecules that determine the directionalities of RGC axons at the OC. It has been shown that vHT radial glial cells express ephrinB2, which binds to EphB1 receptors expressed in ventral-temporal RGC axons and repels the axons toward the ipsilateral optic tract ([@bib30]; [@bib47]). In addition, vascular endothelial growth factor 164 (VEGF164), an isoform of the vascular endothelial growth factor VEGF-A ([@bib39]), and neuronal cell adhesion molecule (NrCAM) expressed in the vHT have been suggested to support the growth of RGC axons across the vHT midline by binding to neuropilin-1 and plexin-A1, respectively ([@bib46]; [@bib12]; [@bib23]). To receive the directional guidance of these molecules at the vHT, RGC axons must pass through the ventral-lateral diencephalic area, where repulsive guidance cues, such as Slit and semaphorins, are expressed at high levels ([@bib13]; [@bib34]). However, the molecules that support RGC axon growth toward the vHT midline are still unknown.

Ventral anterior homeobox 1 (Vax1) is a homeodomain transcription factor expressed in various ventral-medial forebrain-derived structures, including the medial and lateral geniculate eminences, the ventral septum, the anterior entopeduncular area, the preoptic area, the vHT, and the OS ([@bib15]; [@bib2]). Genetic inactivation of *Vax1* in humans and mice causes agenesis of multiple midline structures of the brain, including the anterior commissure, the corpus callosum, and the OC, in addition to the coloboma of the eye ([@bib2]; [@bib14]; [@bib38]). RGC axons in *Vax1*-deficient mice can grow through the OS but cannot access the vHT area and fail to form an OC. *Vax1* is not expressed in RGCs despite its critical roles in growth and fasciculation of RGC axons ([@bib2]; [@bib29]). Therefore, it has been suggested that defects in OC formation in *Vax1*-deficient mouse RGCs might be caused by the loss or gain of axon guidance cues that are potential transcription targets of Vax1 in vHT cells.

Contrary to expectation, we here found that Vax1 promoted RGC axon growth in a transcription-independent manner. Moreover, Vax1 is secreted from vHT cells and binds and enters RGC axons to stimulate axonal growth. This unexpected trafficking of Vax1 to RGC axons was mediated by heparan sulfate proteoglycans (HSPGs), such as syndecan and glypican, expressed in RGC axons. However, Vax1 binding to HSPGs was not sufficient to trigger RGC axon growth; penetration into the RGC axoplasm and subsequent stimulation of local protein synthesis were also necessary. Taken together, our findings reveal an unconventional function of Vax1 as an RGC axon growth factor that enables RGC axons to grow toward the midline during development.

Results {#s2}
=======

Vax1 regulates the RGC axonal growth in a non-cell autonomous manner {#s2-1}
--------------------------------------------------------------------

*Vax1* is expressed in cells located in optic pathway structures, such as the OS and vHT, and plays an essential role in fasciculation of RGC axons and formation of the OC ([@bib2]; [@bib14]). At the vHT of days post coitum 14.5 (E14.5) mouse embryo, Vax1 is expressed in Sox2 (SRY box 2)-positive neural progenitor cells (NPCs) and RC2-detectable nestin-positive radial glia ([Figure 1A,B](#fig1){ref-type="fig"}; top rows), which is known to provide RGC axon guidance cues ([@bib32]). Although the morphology of the chiasm is abnormal in *Vax1*-deficient (*Vax1*^*−/−*^) mice ([@bib2]), these OC-forming cells and several chiasm-localized cues (NrCAM and *Vegfa*) are still present ([Figure 1A,B](#fig1){ref-type="fig"}, bottom rows; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). However, vHT explants from *Vax1*^*−/−*^ mice were unable to attract RGC axons regardless of the *Vax1* gene status of co-cultured retinal explants, whereas wild-type (WT; *Vax1*^+/+^) vHT explants were able to attract RGC axons projected from *Vax1*^*−/−*^ explants as well as WT explants ([Figure 1C,D](#fig1){ref-type="fig"}). We therefore concluded that Vax1 controls the RGC axonal growth in a non-cell autonomous manner, potentially by regulating the expression of unidentified secreted axon-guidance molecules.10.7554/eLife.02671.003Figure 1.Vax1 regulates RGC axonal growth in a non-cell autonomous manner.(**A**) Cells expressing Vax1 (green) in brain sections (coronal; 16 μm) from E14.5 *Vax1*^*+/+*^ (top) and *Vax1*^*−/−*^ (bottom) embryos were detected by co-immunostaining for the NPC marker Sox2 (red) and post-mitotic neuronal marker tubulin-βIII (blue), detected with the Tuj1 antibody. The right-most three columns are the magnified images of dotted boxes in the left column image. The results indicate that Vax1 is expressed in a subpopulation of Sox2-positive NPCs (arrowheads) but is not detectable in Tuj1-positive neurons. (**B**) Vax1-expressing cells in the vHT were also compared with RC2-positive radial glia. Arrowheads indicate RC2-positive radial glial cells expressing Vax1. Scale bars: 50 μm. (**C**) The vHT and dorsal neural retina (NR) were isolated from WT (*Vax1*^+/+^) and *Vax1-*knockout (*Vax1*^−/−^) E13.5 mouse embryos and co-cultured in a combinatorial manner for 48 hr. The explants were fixed and immunostained with an anti-NF160 antibody (α-NF160; red); nuclei were counterstained with DAPI (blue). Dotted boxes indicate the area magnified in each inset. Red dotted lines link centers of retinal explants and vHT explants. Scale bars: 500 μm. (**D**) The angular distribution of RGC axons in images was measured by counting pixels containing immunostaining for the axon marker NF160 (axon counts), as described in 'Materials and methods', and presented graphically. +, forward direction angle segment; 0, neutral direction angle segments; −, reverse direction angle segment. The values in the bar are averages, error bars denote standard deviations (SDs), and numbers under *y*-axis labels are the numbers (n) of explants analyzed from three independent experiments. *p*-values determined by the analysis of variance (ANOVA) are between 0.01 and 0.005.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.003](10.7554/eLife.02671.003)10.7554/eLife.02671.004Figure 1---figure supplement 1.Expression of RGC axon attractive cues in *Vax1*^*−/−*^ mouse vHT.To determine whether defective projection of RGC axons to the vHT midline of *Vax1*^*−/−*^ mice resulted from defective expression of RGC axon growth factors, such as VEGF164 or NrCAM ([@bib46]; [@bib12]), in the vHT, we compared expression of these cues between WT (Vax1+/+) and Vax1-knockout (Vax1−/−) mouse embryos. Expression of *Vegfa* mRNA (**A**) and NrCAM protein in E14.5 *Vax1*^*+/+*^ and *Vax1*^*−/−*^ mouse embryonic sections (coronal; 16 μm) was examined by in situ RNA hybridization (ISH; **A**) and immunofluorescence staining (IF; **B**), respectively. The vHT of the *Vax1*^*−/−*^ mouse brain retained, but expanded, expression of both *Vegfa* and NrCAM. Scale bars: 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.004](10.7554/eLife.02671.004)

Vax1 is a secreted protein {#s2-2}
--------------------------

To identify Vax1-regulated secreted factors that control RGC axonal growth from co-cultured retinal explants, we overexpressed mouse Vax1 in COS7 cells. RGC axons from retinal explants grew preferentially toward co-cultured Vax1-expressing COS7 cell aggregates, whereas RGC axons projected in random directions upon co-incubation with untransfected or Vax2-overexpressing COS7 cell aggregates ([Figure 2A,B](#fig2){ref-type="fig"}). Because Vax2 shares an identical homeodomain with Vax1 ([@bib1]), these results indicate that the RGC axon growth stimulatory activity is specific for Vax1.10.7554/eLife.02671.005Figure 2.Vax1 homeodomain protein is a secreted protein.(**A**) COS7 cells overexpressing Myc-tagged mouse Vax1, Vax1(R152S), or Vax2 were co-cultured with E13.5 mouse retinal explants (NR) for 48 hr. The explants were then stained with a rabbit anti-Myc antibody (green) and a mouse anti-NF160 antibody (red). Nuclei of explant cells were counterstained with DAPI (blue). Dotted red lines indicate the connections between the centers of two explants. Scale bars: 500 μm (left column) and 100 μm (magnified immunostained images in two right-hand columns). (**B**) The angular distribution of RGC axons was measured as described in [Figure 1D](#fig1){ref-type="fig"}. The values in the bar are averages and error bars denote SDs. Numbers under *y*-axis labels are the number of explants analyzed from three independent experiments. *p*-values are between 0.01 and 0.005 (ANOVA). (**C**) Growth medium from COS7 cells overexpressing Myc-Vax1, Myc-Vax1(R152S), or Myc-Vax2 was collected, and the presence of Vax protein in the growth medium (GM) was detected by Western blotting (WB) with an anti-Myc antibody. The relative amounts of secreted protein were also measured by analyzing the level of proteins in the COS7 cell lysates (CL; 5% of total). (**D**) vHTs isolated from WT and *Vax1*^*−/−*^ E13.5 mouse embryos were cultured for 24 hr, after which GM was collected for detection of secreted Vax1 protein by Western blotting. CL, cell lysates of vHT explants (5% of total). (**E**) Cerebrospinal fluid (CSF) from E14.5 mouse embryos (n = 20) was collected, a supernatant fraction (S3) was separated from cell debris (P2) by step-wise centrifugation (see 'Materials and methods' for details), and the presence of Vax1 protein was examined by Western blotting. The presence of β-tubulin, a cytoplasmic protein, was also examined in GM and CSF fractions to check for the possible non-specific release of intracellular proteins from dead cells. CL, E14.5 vHT cell lysates (2% of total lysates from one embryonic vHT).**DOI:** [http://dx.doi.org/10.7554/eLife.02671.005](10.7554/eLife.02671.005)10.7554/eLife.02671.006Figure 2---figure supplement 1.Relative transcriptional activities of Vax1 mutants used in this study.HEK293T cells (10^5^) were transfected with pcDNA6-V5 expression vectors (1 μg) for Vax1, Vax1(R152S), or Vax1(WF/SR) together with pGL3-Tcf7l1-luciferase (0.2 μg) ([@bib45]) and pCMV-β-gal (0.2 μg) plasmids. Luciferase activity in the transfected cells was measured 24 hr post-transfection. The values were then normalized to β-galactosidase activity in the same cells to obtain the relative luciferase activity of the cells. The values are averages obtained from three independent experiments, and error bars denote SDs (\*\*p \< 0.001; ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.02671.006](10.7554/eLife.02671.006)10.7554/eLife.02671.007Figure 2---figure supplement 2.Interference of Vax1 intercellular transfer by sequestering extracellular Vax1.E13.5 retinal explants were co-incubated with Myc-Vax1 transfected COS7 cell aggregates for 24 hr in the presence of rb-IgG (1 μg/ml; top) or anti-Vax1 antibody (α-Vax1; 1 μg/ml; bottom). The explants were then fixed for immunostaining with mouse anti-NF160 antibody (red) and rabbit anti-Myc antibody (green). Immunostaining images of dotted boxed area in the left column are shown in the right column. Arrows indicate Vax1-Myc proteins internalized to RGC axons. Scale bars: left, 500 μm; right, 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.007](10.7554/eLife.02671.007)

We next examined whether Vax1-induced RGC axonal growth is dependent on Vax1 transcription activity by co-incubating retinal explants with COS7 cells expressing a transcriptionally inactive Vax1(R152S) mutant ([Figure 2](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This mutation was reported in a human patient who exhibited coloboma, cleft palate, and agenesis of corpus callosum (ACC), phenotypic manifestations similar to those of *Vax1*^*−/−*^ mice ([@bib38]). Unexpectedly, we found that Vax1(R152S)-expressing COS7 cells were also able to induce RGC axonal growth as efficiently as WT Vax1-expressing COS7 cells ([Figure 2A](#fig2){ref-type="fig"}, third row, B), suggesting that Vax1 induces RGC axonal growth in a transcription-independent manner.

More strikingly, Vax1 and Vax1(R152S) proteins were not only expressed in transfected COS7 cells, they were also detectable in neurofilament 160 kDa (NF160)-positive RGC axons projecting from co-cultured retinal explants ([Figure 2A](#fig2){ref-type="fig"}, right two columns). These axonal Vax1-immunostaining signals were remarkably decreased in the presence of a rabbit anti-Vax1 polyclonal antibody (α-Vax1) that sequesters Vax1 in the growth medium ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Furthermore, Vax1 and Vax1(R152S) proteins were found in the growth medium of transfected COS7 cells, whereas Vax2 protein was not ([Figure 2C](#fig2){ref-type="fig"}). Since the viability of the transfected COS7 cells were not different from each other (data not shown), these results suggest that Vax1 proteins in the growth medium and co-cultured RGC axons did not originate from dead cells. Similar to overexpressed Vax1 in COS7 cells, endogenous Vax1 expressed in vHT explants was detectable in the growth medium ([Figure 2D](#fig2){ref-type="fig"}). Furthermore, Vax1 protein was also identified in the cerebral spinal fluid (CSF) of E14.5 mouse embryos ([Figure 2E](#fig2){ref-type="fig"}), suggesting that Vax1 is secreted in vivo as well as in vitro.

Vax1 has retinal axon growth factor activity {#s2-3}
--------------------------------------------

We further tested whether secreted Vax1 is capable of directly binding to RGC axons and regulating axonal growth using purified recombinant Vax1 protein. Time-lapse recordings of RGC axons revealed that fluorescein isothiocyanate (FITC)-labeled, His-tagged Vax1 (Vax1-His) protein added to the growth medium of retinal explants accumulated in RGC axons and exerted strong growth stimulatory effects on them ([Figure 3A,B](#fig3){ref-type="fig"}; [Videos 1--3](#video1 video2 video3){ref-type="other"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The axon growth stimulating effects of Vax1-His were applied equally to retinal quadrants ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), implicating Vax1 is not a region-specific axon growth factor. The transcriptionally inactive Vax1(R152S)-His mutant protein was also detectable in RGC axons and stimulated axonal growth as efficiently as WT Vax1-His ([Figure 3C,D](#fig3){ref-type="fig"}), suggesting that extracellular Vax1 moves to RGC axons and induces axonal growth in transcription-independent manner. Despite that Vax2 is not secreted ([Figure 2C](#fig2){ref-type="fig"}), the ability of recombinant Vax2-His to be internalized and induce RGC axonal growth is almost equivalent to that of Vax1 ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}), implicating that internalization but not secretion is a conserved characteristic of VAX transcription factors.10.7554/eLife.02671.008Figure 3.Vax1 protein is a retinal axon growth factor.(**A**) E13.5 mouse retinal explants were cultured for 24 hr and then treated with 6X-His-FITC peptide (100 ng/ml) or recombinant Vax1-His-FITC protein (500 ng/ml) for an additional 24 hr. Images of RGC axons were taken every 15 min for 16 hr before immunostaining with anti-Vax1 and anti-His antibodies ([Videos 1 and 2](#video1 video2){ref-type="other"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The accumulation of 6X-His-FITC and Vax1-His-FITC in growing RGC axons was also visualized by detecting FITC fluorescence signals (inset images). Red arrowheads indicate the area magnified in each inset. (**B**) The changes in RGC axonal length during the recording were plotted after adjusting the initial length to 100%. (**C**) Retinal explants treated with 6X-His (25 ng/ml), Vax1-His (100 ng/ml), or Vax1(R152S)-His (100 ng/ml) for 24 hr were stained with rabbit anti-Vax1 (green) and mouse anti-NF160 (red) antibodies to visualize Vax1 protein in RGC axons. Arrowheads indicate the area magnified in each inset. Scale bars: 500 μm. (**D**) Relative numbers of axon bundles projecting from retinal explants were indirectly measured by counting the pixels containing NF160 immunofluorescence in RGC axons between 20 and 40 μm from the rim of the explants (total axon bundle). The relative thickness of individual axon bundles was also measured by comparing the total pixel counts of NF160 in the 20--40-μm area (individual axon bundle). The values in the graph are averages expressed relative to those of 6X-His peptide-treated samples, presented as 1; error bars denote SDs (\*\*p \< 0.001; ANOVA). The scores on top of the graph columns are the number of axons (individual axon bundle) and the number of explants (total axon bundle) analyzed, respectively. Results were obtained from three independent experiments. The number of explants analyzed: for 6X-His, n = 10; Vax1-His, n = 11; Vax1(R152S)-His, n = 6. (already shown in total axon bundle).**DOI:** [http://dx.doi.org/10.7554/eLife.02671.008](10.7554/eLife.02671.008)10.7554/eLife.02671.009Figure 3---figure supplement 1.Penetration of exogenous Vax1 protein into RGC axons.Retinal explants isolated from E13.5 mouse embryos were cultured for 24 hr before recording phase contrast and fluorescence images every 15 min on a Zeiss Axio Observer Z1 inverted microscope. After 180 min of recording, 6X-His-FITC peptide (100 ng/ml) or Vax1-His-FITC protein (500 ng/ml) was added to the growth medium. The images were then combined into video clips, provided in [Videos 1 and 2](#video1 video2){ref-type="other"}. After recording for 16 hr, the explants were washed with PBS, and Vax1 protein present at the surface of axons was detected by incubating with rabbit α-Vax1 (green) in growth medium for 20 min. The explants were then washed three times with PBS and fixed in 4% PFS/PBS for 1 hr prior to the detection of 6X-His peptide or Vax1-His protein inside and on the surface of axons using mouse anti-His antibody (red). The explants were then further incubated with Alexa 488-labeled α-rabbit IgG and Cy3-labeled α-mouse IgG, and the distribution of Vax1 on the surface and within the intracellular space of RGC axons was analyzed by confocal microscopy. Phase contrast images in the left column show representative snapshot images from [Videos 1 and 2](#video1 video2){ref-type="other"}. Immunostained images in the right columns correspond to dotted boxes in the phase contrast images in the left column. Arrows indicate Vax1-His proteins internalized to RGC axons. Scale bars: 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.009](10.7554/eLife.02671.009)10.7554/eLife.02671.010Figure 3---figure supplement 2.Region non-selective stimulation of retinal axonal growth by recombinant Vax1.Dark field images of retinal quadrant explants were taken before (0 hr) and after (24 hr) treating them with 6X-His peptide (25 ng/ml; white column) or Vax1-His protein (100 ng/ml; black column). The changes in axonal length during the 24-hr incubation period were shown in a graph. The values in the graph are averages and error bars denote SDs. The scores in the graph columns are the numbers of axons analyzed. Numbers of explants analyzed are shown on the top of the columns. *p*-values were determined by Student *t*-test (\*\*p \< 0.001). The results were obtained from two independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.010](10.7554/eLife.02671.010)10.7554/eLife.02671.011Figure 3---figure supplement 3.Recombinant Vax2 is capable for inducing RGC axon growth in vitro.(**A**) E13.5 WT retinal explants were incubated in the presence and absence of Vax2-His (100 ng/ml) for 24 hr. The explants were then fixed for immunostaining with rabbit anti-Vax2 antibody (green) and mouse anti-NF160 antibody (red). DAPI (blue), nuclear counter staining. Immunostaining images in the bottom panel are magnified versions of dotted boxed area in the top panel. Arrow indicates Vax2-His proteins internalized to RGC axons. Scale bars are 500 μm (top) and 100 μm (bottom), respectively. (**B**) Dark field images of the explants were taken before (0 hr) and after (24 hr) incubation period. The changes in axonal length during the 24-hr incubation period were measured and compared with untreated control samples. The values in the graph are averages and error bars denote SDs. The scores on top of the graph columns are the number of axons analyzed. The number of explants analyzed are: 6X-His, n = 5; Vax1, n = 4. *p*-values were determined by Student *t* test (\*\**p* \< 0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.02671.011](10.7554/eLife.02671.011)Video 1.Time-lapse video of E13.5 mouse retinal explants cultured in the presence of 6X-His-FITC peptides (100 ng/ml) as described in 'Materials and methods'.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.012](10.7554/eLife.02671.012)10.7554/eLife.02671.012Video 2.Time-lapse video of E13.5 mouse retinal explants cultured in the presence of Vax1-His-FITC proteins (500 ng/ml) as described in 'Materials and methods'.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.013](10.7554/eLife.02671.013)10.7554/eLife.02671.013Video 3.Time-lapse video of E13.5 mouse retinal explants cultured in the presence of 6X-His-FITC peptides (500 ng/ml) as described in 'Materials and methods'.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.028](10.7554/eLife.02671.028)10.7554/eLife.02671.028

In vivo evidence for intercellular transfer of Vax1 {#s2-4}
---------------------------------------------------

We next sought evidence for the transfer of Vax1 to RGC axons in vivo. As reported previously ([@bib15]; [@bib2]), *Vax1* mRNA is expressed in RGC axon-associated structures, including the OD, the OS, and the vHT, but not the retina, of E14.5 mice ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). However, an examination of Vax1 protein distribution in E14.5 *Vax1*^*lacZ/+*^ heterozygous mouse embryos showed that Vax1 was detectable in the retina as well as the OS and OD ([Figure 4B](#fig4){ref-type="fig"}, top row). In these mice, β-galactosidase (β-gal) is expressed from a *lacZ* gene replacing one *Vax1* gene locus while Vax1 is expressed from the other intact *Vax1* gene locus ([@bib14]); therefore, β-gal should be expressed in cells expressing Vax1. However, we found that RGCs in *Vax1*^*lacZ/+*^ mice did not express β-gal but did express Vax1, this contrasts with OS APCs which co-expressed Vax1 and β-gal ([Figure 4B](#fig4){ref-type="fig"}, top row). Vax1-immunostaining signals were completely absent in RGCs as well as β-gal-positive OS APCs from homozygous *lacZ* knock-in (*Vax1*^*lacZ/lacZ*^) *Vax1*^*lacZ/lacZ*^ littermates, suggesting that Vax1 immunostaining signals in the *Vax1*^*lacZ/+*^ mouse RGC were specific ([Figure 4B](#fig4){ref-type="fig"}, bottom row). Collectively, these data demonstrate that Vax1 protein in RGCs might originate from the neighboring Vax1/β-gal double-positive APCs in the OS or NPCs and radial glia in the vHT ([Figure 4B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}).10.7554/eLife.02671.014Figure 4.Mouse RGC axons import Vax1 protein.(**A**) *Vax1* mRNA expression in E14.5 WT (*Vax1*^*+/+*^) mouse retinas was examined by in situ RNA hybridization using a \[^33^P\]-CTP-labeled antisense Vax1 probe, as described elsewhere ([@bib29]). *Vax1* transcripts were detected in the OS and OD, but not in the neural retina (NR). This in situ hybridization signal was absent in *Vax1*^*lacZ/lacZ*^ homozygous knock-in mouse eyes (bottom). (**B**) The distribution of Vax1 protein in the NR (i and iii) and OS (ii and iv) of E14.5 *Vax1*^*lacZ/+*^ and *Vax1*^*lacZ/lacZ*^ embryos was compared with that of β-gal expressed from the *lacZ* gene at the *Vax1* locus by co-staining with rabbit anti-Vax1 (green) and mouse anti-β-gal (red) antibodies. Vax1 protein detected in *Vax1*^*lacZ/+*^ mouse retinal cells, where β-gal signals were absent, is presumed to originate from external sources that co-express Vax1 and β-gal. Red dots in (iii) are non-specific background β-gal immunostaining. (**C**) Distribution of Vax1 in RGC axons and cell bodies was examined by co-immunostaining for Vax1 (green) and the RGC axonal marker NF160 (red). Nuclei were counterstained with DAPI (blue). Arrowheads in (ii) indicate Vax1 protein that co-localizes with NF160, whereas arrows point to Vax1 in APC nuclei. Vax1 immunostaining signals were completely absent in the OS and NR of *Vax1*^*lacZ/lacZ*^ mice, whereas NF160 immunostaining was still detectable in defasciculated RGC axons (iii and iv). (**D**) Sections of E18.5 WT and *Vax1*^*lacZ/lacZ*^ mouse retinas (top) and optic nerves (ON; bottom) were immunostained with rabbit anti-Vax1 antibody and gold (25 nm)-labeled anti-rabbit IgG. Subcellular localization of Vax1 proteins was then examined by electron microscopy. Arrowheads in RGC images point to Vax1 proteins in the intracellular vesicle, whereas arrows in the images indicate Vax1 proteins bound to the extracellular surface of the RGC plasma membrane (top). Arrowheads in APC images indicate Vax1 proteins in trafficking vesicles, whereas arrows mark Vax1 proteins associated with chromatin in the nucleus (bottom). Scale bars in (**A**) to (**C**): 200 μm (left column) and 20 μm (right two columns). Scale bars in (**D**): 0.5 μm (left column) and 0.2 μm (right two columns).**DOI:** [http://dx.doi.org/10.7554/eLife.02671.014](10.7554/eLife.02671.014)10.7554/eLife.02671.015Figure 4---figure supplement 1.Expression of Vax1 mRNA and protein in the vHT area.(**A**) Vax1 mRNA was detected in the HT, hypothalamic cell cord (HCC), and optic nerve (ON) approaching the OC of E14.5 WT (*Vax1*^*+/+*^) embryonic brains (top left). Vax1 proteins, assessed by immunostaining with an anti-Vax1 antibody, were also detectable in these structures (top right). However, Vax1 immunostaining signals as well as *Vax1* mRNA were absent in these structures in the brains of *Vax1*^*−/−*^ littermates (bottom). (**B**) Vax1 localization in E14.5 *Vax1*^*lacZ/+*^ mouse vHT cells, which also express β-gal from one *Vax1* locus, was examined by co-immunostaining for Vax1 and β-gal. All cells that expressed β-gal also expressed Vax1 (arrowhead), but some Vax1-positive cells lacked β-gal (arrow). Vax1 was not detected in the brains of *Vax1*^*lacZ/lacZ*^ homozygous knock-in mice, which express β-gal from both *Vax1* loci, confirming the specificity of Vax1 immunostaining. Scale bars: 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.015](10.7554/eLife.02671.015)10.7554/eLife.02671.016Figure 4---figure supplement 2.Cytoplasmic localization of Vax1 in RGCs.Sections of E18.5 WT (top) or *Vax1*^*lacZ/lacZ*^ mouse retinas (bottom) were immunostained with rabbit α-Vax1 and gold (25 nm)-labeled anti-rabbit IgG and analyzed by electron microscopy, as described in [Figure 4D](#fig4){ref-type="fig"}. Arrowheads indicate Vax1 proteins in trafficking vesicles, whereas arrows mark soluble Vax1 in the cytoplasm (top).**DOI:** [http://dx.doi.org/10.7554/eLife.02671.016](10.7554/eLife.02671.016)

Vax1 protein in OS APCs was present mainly in nuclei, whereas a majority of Vax1 protein in β-gal-negative RGCs was non-nuclear ([Figure 4B](#fig4){ref-type="fig"}, i and ii). Furthermore, Vax1 co-localized with NF160 in E14.5 WT mouse RGC axons but was lost in *Vax1*^*lacZ/lacZ*^ mouse RGC axons ([Figure 4C](#fig4){ref-type="fig"}). These Vax1 localization patterns in the OS APCs and RGCs were further confirmed by immuno-transmission electron microscopy. Vax1 protein was highly enriched at the extracellular part of the RGC membrane and was also detected in the cytoplasm and intracellular vesicles ([Figure 4D](#fig4){ref-type="fig"}, top row; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Vax1 protein in OS APCs was not only enriched in nuclei but was also detectable in cytoplasmic membrane structures ([Figure 4D](#fig4){ref-type="fig"}, bottom row). These results therefore suggest that OS- and/or vHT-secreted Vax1 might enter RGCs after docking with the RGC axon membrane.

Intercellular transfer of Vax1 is necessary for RGC axonal growth {#s2-5}
-----------------------------------------------------------------

To investigate whether the secreted Vax1 is necessary for the growth of RGC axons toward vHT explants, we sequestered extracellular Vax1 using α-Vax1. α-Vax1 not only interfered with the transfer of Vax1 from vHT cells to RGC axons, it also antagonized RGC axonal growth toward vHT explants ([Figure 5A](#fig5){ref-type="fig"}, center). In contrast, neither rb-IgG (pre-immune rabbit IgG) nor α-Vax2 influenced Vax1 transfer into RGC axons or RGC axonal growth toward vHT explants ([Figure 5A](#fig5){ref-type="fig"}, left and right). α-Vax1 treatment not only reduced the population of retinal axons growing toward the vHT ([Figure 5B](#fig5){ref-type="fig"}), it also decreased the total number of retinal axons growing from the explants ([Figure 5C](#fig5){ref-type="fig"}), suggesting an axogenic activity as well as an axon growth-stimulating activity of extracellular Vax1.10.7554/eLife.02671.017Figure 5.Secreted Vax1 protein is necessary for RGC axon growth.(**A**) vHTs and retinas isolated from E13.5 mouse embryos were co-cultured for 48 hr in the presence of pre-immune rabbit IgG (rb-IgG; 1 μg/ml), anti-Vax1 (α-Vax1; 1 μg/ml), or anti-Vax2 (α-Vax2; 1 μg/ml) antibodies. Vax1 localization in RGC axons was then determined by staining explants with rabbit α-Vax1 (green) and mouse α-NF160 (red). Arrowheads indicate the area magnified in each inset. Scale bars: 500 μm. (**B**) The distribution of RGC axons in each angle segment was determined as described in 'Materials and methods'. The values in the bar are averages, and error bars denote SDs. *p*-values are between 0.01 and 0.005 (ANOVA). (**C**) Total image pixel counts of NF160 immunofluorescence in a 20--40-μm area were compared to obtain the relative number of axons projected from each explant. Scores under *y*-axis labels of (**B**) and (**C**) are the numbers of explants analyzed in three independent experiments (\*\*p \< 0.001; ANOVA). (**D**) Slabs of mouse heads including eyes, forebrain, and midbrain structures were prepared from E13.5 WT mouse embryos. The third brain ventricles of mouse-head slabs were then implanted with collagen gels containing rb-IgG (1 μg/ml) or α-Vax1 (1 μg/ml) and subsequently incubated at 37°C in a CO~2~ incubator for 12 hr (top row; see 'Materials and methods' for details). The slabs were then fixed and frozen to obtain horizontal sections (18 μm thick). The slides containing optic nerves (ON) were then further co-stained with α-Vax1 (green) and α-NF160 (red) and analyzed using an Olympus FV1000 confocal microscope. Images in the bottom row are magnifications of dotted boxes in the top row. Scale bars: 200 μm. Relative fluorescence intensities of Vax1- and/or NF160-positive immunostaining intensities in the midline area (dotted box) were measured using ImageJ software and presented graphically. White column, rb-IgG; black column, α-Vax1. The values are relative intensities compared with rb-IgG-treated samples; error bars denote SDs and values on the top of graph columns are number of slabs analyzed (\*p \< 0.01; Student *t* test). A, anterior; P, posterior; M, medial; L, lateral; \*, optic chiasm; V3, third ventricle.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.017](10.7554/eLife.02671.017)

The roles of extracellular Vax1 in RGC axon growth were also investigated in vivo. Collagen gels releasing rb-IgG or α-Vax1 were implanted in the third ventricle of E13.5 mouse embryonic brain slabs to sequester extracellular Vax1 in the vHT area ([Figure 5D](#fig5){ref-type="fig"}, diagram on top panel). Mouse embryos implanted with α-Vax1-releasing gels showed a remarkable reduction in RGC axons accessing the midline compared with embryos implanted with rb-IgG-releasing gels ([Figure 5D](#fig5){ref-type="fig"}). In α-Vax1-implanted mouse embryos, a significant number of RGC axons showed reduced Vax1 immunoreactivity and stopped at the lateral wall of the ventral diencephalon, properties similar to those observed in *Vax1*^*−/−*^ mice ([@bib2]) ([Figure 5D](#fig5){ref-type="fig"}, bottom row). Taken together, these results suggest that extracellular Vax1 is necessary for RGC axonal growth to the ventral midline.

Heparan sulfate proteoglycan regulates Vax1 intercellular transfer {#s2-6}
------------------------------------------------------------------

Intercellular transfer has also been reported for other homeodomain transcription factors, such as engrailed-2 (En2) and orthodenticle homeobox 2 (Otx2) ([@bib19]; [@bib44]; [@bib40]). However, little is known about the regulatory mechanisms underlying the trafficking of homeodomain transcription factors. We therefore searched for the gene encoding proteins capable of modifying the intercellular transfer of Vax1 in *Drosophila* ([Figure 6](#fig6){ref-type="fig"}; *screening results are unpublished*). One of the genes isolated in this screen encodes the transmembrane heparan sulfate proteoglycan (HSPG) protein, syndecan (Sdc) ([@bib41]). HSPGs, including Sdc2, Sdc3, and glypican 1 (Glp1), are highly expressed in mouse RGC axons and have been proposed to play critical roles in RGC axon guidance in various vertebrates ([@bib8]; [@bib17]; [@bib24]; [@bib35]). We thus focused on the potential role of HSPGs as receptors for Vax1 in RGC axons.10.7554/eLife.02671.018Figure 6.Regulation of intercellular Vax1 transfer by HSPGs in *Drosophila* wing imaginal discs.Vax1-EGFP (green) and DsRed (red) were co-expressed under the control of *Ptc-Gal4* in the A/P boundary cells of *Drosophila* wing imaginal discs in *wt* (top row) and *Sdc* mutant (*Sdc*^*23*^; second row) flies. The number of cells positive for Vax1-EGFP but negative for DsRed at the posterior part of the wing disc was increased in *Sdc*^*23*^ flies. In contrast, the number of Vax1-EGFP-positive cells in the posterior wing disc was significantly decreased in fly embryos that co-expressed Sdc (third row) or Dlp (bottom row) together with Vax1-EGFP and DsRed. Diagrams in the right column show the distribution of Vax1-EGFP-positive cells (green) and DsRed (red) in the corresponding fly wing discs. Scale bars: 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.018](10.7554/eLife.02671.018)

Vax1-GFP protein was co-expressed with DsRed protein in the A/P (anterior/posterior) boundary cells of *Drosophila* wing imaginal disc under the control of a *Ptc-Gal4* driver. Vax1-EGFP, but not DsRed, was transferred to neighboring cells, results similar to those observed in the mammalian systems ([Figure 6](#fig6){ref-type="fig"}, top row). However, the transfer of Vax1-EGFP to neighboring wing disc cells was suppressed upon co-expression of Sdc in the A/P boundary cells ([Figure 6](#fig6){ref-type="fig"}, third row). Overexpressed dally-like protein (Dlp), a *Drosophila* homolog of Glp, also suppressed Vax1 transfer in the same manner as Sdc ([Figure 6](#fig6){ref-type="fig"}, bottom row), suggesting that the intercellular transfer of Vax1 in *Drosophila* wing imaginal disc cells is mediated by HSPGs but not specifically by Sdc. These results also imply that these overexpressed HSPGs in the A/P boundary cells captured co-expressed Vax1-EGFP protein, thereby interfering with the transfer of Vax1-EGFP to neighboring cells ([Figure 6](#fig6){ref-type="fig"}, diagram in the right column). Conversely, Vax1-EGFP proteins were transferred farther in the *Sdc* mutant (*Sdc*^*23*^) wing imaginal disc, where total HSPG levels were reduced owing to the loss of Sdc ([Figure 6](#fig6){ref-type="fig"}, second row).

Heparan sulfate-dependent binding of Vax1 to HSPGs is required for Vax1-induced RGC axonal growth {#s2-7}
-------------------------------------------------------------------------------------------------

HSPG-regulated Vax1 transfer was further investigated in the mammalian systems. We found that Vax1, but not Vax2, interacted with Sdc2 in E14.5 mouse optic nerves as well as with overexpressed Sdc1 and Sdc2 in human embryonic kidney (HEK) 293T cells ([Figure 7A](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}). Sdc2-N, lacking the C-terminal cytoplasmic domain, was able to interact with Vax1, whereas Sdc2-C, which lacks the N-terminal extracellular domain, failed to interact with Vax1 ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}), suggesting that Vax1 binds to the extracellular domain of Sdc.10.7554/eLife.02671.019Figure 7.Vax1 binding to HSPGs is necessary for RGC axonal growth.(**A**) Interaction between Vax1 and Sdc2 in the E14.5 mouse optic nerve was investigated by immunoprecipitation with a rabbit anti-Vax1 (top) or goat anti-Sdc2 (bottom) antibody and subsequent Western blotting with reciprocal antibodies. The specificity of anti-Vax1 and anti-Sdc2 antibodies was confirmed by immunoprecipitation with pre-immune rabbit IgG (rb-IgG) and goat IgG (gt-IgG), respectively. (**B**) Immunoprecipitation of Vax1 in the E14.5 mouse OS was also performed in the presence or absence of heparin (1 mg/ml) to determine whether the Vax1 protein bound to HS sugar groups of Sdc2, Sdc3, and/or Glp1 HSPGs expressed in RGC axons. (**C**) Vax1-His protein (final concentration, 2 μg/ml) was incubated at 4°C for 1 hr with Sepharose 4B resin (Sigma, St. Louis, MO, USA) coated with HS or CS. The resins were washed three times with PBS, and Vax1 protein bound to the resins was eluted in SDS sample buffer for subsequent SDS-PAGE on 10% gels and Western blotting with α-Vax1. Relative intensities of Vax1 bands in Western blot images were analyzed using ImageJ software. (**D**) Retinal explants were treated with heparinase I (2.5 U/ml) or ChnaseABC (2.5 U/ml) for 3 hr and then incubated with 6X-His peptide (25 ng/ml) or Vax1-His recombinant protein (100 ng/ml) for an additional 24 hr. The presence of Vax1-His in RGC axons was then examined by co-immunostaining with rabbit anti-Vax1 (green), mouse anti-NF160 (red), and goat anti-Sdc3 (blue) antibodies. Dotted boxes indicate the area magnified at right. Scale bars: 500 μm. (**E**) The graph shows relative distances that RGC axons grew during the 24-hr incubation period. The values in the graph are averages of fold ratios compared with those of 6X-His-treated samples, error bars denote SDs, and the scores on top of graph columns are the number of axons analyzed (\*p \< 0.01, \*\*p \< 0.001; ANOVA). Results were obtained from three independent experiments. Numbers of explants analyzed: 6X-His, n = 6; Vax1, n = 7; heparinase, n = 5; chondroitinase, n = 5; Vax1+heparinase I, n = 6; Vax1+ChnaseABC, n = 6.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.019](10.7554/eLife.02671.019)10.7554/eLife.02671.020Figure 7---figure supplement 1.Molecular determination of the interaction between Vax1 and Sdc.Vax1 (**A**) or Vax2 (**B**) was co-expressed with GFP-tagged Sdc1 and Sdc2 in HEK293T cells. GFP-fused Sdc1 and Sdc2 protein complexes were isolated by immunoprecipitation (IP), and Vax1 and Vax2 proteins in GFP-Sdc1 and GFP-Sdc2 immune complexes were detected by Western blotting using α-Vax1 (**A**) or α-Vax2 (**B**). (**C**) The Vax1-interacting domains of Sdc2 were examined by co-expressing Vax1 with Sdc2-N, which lacks the cytoplasmic domain, or with Sdc2-C, which lacks the extracellular domain. GFP-Sdc-N or GFP-Sdc-C protein that co-immunoprecipitated with Vax1 was detected by Western blotting with α-GFP. Relative levels of Vax1, Vax2, and GFP-Sdc2 proteins in cell lysates (CL) used for IP were also examined by Western blotting (bottom two panels in **A**--**C**).**DOI:** [http://dx.doi.org/10.7554/eLife.02671.020](10.7554/eLife.02671.020)10.7554/eLife.02671.021Figure 7---figure supplement 2.Co-localization of Vax1 and Sdc3 in RGC axons.(**A**) Distribution of Vax1 and Sdc3 in E14.5 mouse embryonic eyes was examined by co-immunostaining with rabbit anti-Vax1 (green) and goat anti-Sdc3 (red) antibodies. Image in the third is a merged magnification of area marked by dotted boxes in the left two images. Plots in the right column indicate fluorescence intensities of areas marked by dotted lines in the third. Arrowheads on plots indicate fluorescence intensities of the corresponding points in the images. N, nasal; T, temporal. Scale bars: 200 μm (left two panel) and 20 μm (third panel). (**B**) Retinal explants isolated from dorsal-temporal (DT) and ventral-temporal (VT) parts of E13.5 mouse retinas were treated with Vax1-His protein (100 ng/ml) for 24 hr. The explants were then fixed for immunostaining with rabbit anti-Vax1 (green), mouse anti-NF160 (red), and goat anti-Sdc3 (blue) antibodies. The localization of Vax1 and Sdc3 in NF160-positive RGC axons was examined by confocal microscopy (see details in 'Materials and methods'). Scale bars: 500 μm (left column) and 50 μm (magnified images at right).**DOI:** [http://dx.doi.org/10.7554/eLife.02671.021](10.7554/eLife.02671.021)

The extracellular domain of Sdc is attached by heparan sulfate (HS) sugars ([@bib4]); thus, Vax1 could interact with the sugar groups as well as the protein backbone of Sdc. To determine the potential binding of Vax1 to HS side chains of Sdc2 in RGC axons, we used co-immunoprecipitation assays to test whether excess free heparin competed with HS side chains of HSPGs, including Sdc2, Sdc3, and Glp1, for binding to Vax1. Vax1 interactions with each of these HSPGs expressed in RGC axons in E14.5 optic nerves were disrupted in the presence of free heparin, whereas interactions with Pax2 (paired homeobox 2), which complexes with Vax1 in OS APCs, were not ([Figure 7B](#fig7){ref-type="fig"}). Moreover, recombinant Vax1-His specifically bound HS-sepharose resin with high affinity ([Figure 7C](#fig7){ref-type="fig"}). Collectively, these results suggest that Vax1 preferentially binds to HS side chains of HSPG proteins expressed in RGC axons.

We also examined the influence of Vax1 binding to HSPGs on RGC axon growth. Sdc3 was expressed in E14.5 mouse RGCs in a non-polarized manner and co-localized with Vax1 in RGC axons ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). The growth stimulatory effects of Vax1 on RGC axons were abolished by the treatment of retinal explants with heparinase I, which cleaves heparin and HS sugar chains, but not by incubation with chondroitinase ABC (ChnaseABC), which digests chondroitin sugar chains ([@bib4]; [Figure 7D,E](#fig7){ref-type="fig"}). Heparinase I treatment also decreased the immunostaining intensity of exogenously provided Vax1-His in RGC axons ([Figure 7D](#fig7){ref-type="fig"}). Neither heparinase I nor ChnaseABC influenced RGC axon growth in the absence of Vax1 ([Figure 7D,E](#fig7){ref-type="fig"}). Collectively, these results suggest that the binding of Vax1 to HSPGs is necessary for the induction of RGC axonal growth.

Vax1-induced RGC growth requires local protein synthesis {#s2-8}
--------------------------------------------------------

Secreted Vax1 not only bound to HSPGs at the RGC cell surface, it also moved into the RGC axoplasm by exploiting the cell-penetrating property of its homeodomain ([@bib20]; [Figure 4D](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). It is therefore possible that Vax1 stimulates RGC axonal growth either by acting as a ligand for HSPGs or by regulating cytoplasmic events after penetration. To answer this question, we tested the function of a Vax1(WF/SR) mutant, in which conserved Trp147 and Phe148 amino acids responsible for cell penetration were replaced with Ser167 and Arg148 ([@bib19]); this mutant lacks the ability to cross the cell membrane but remains capable of binding to Sdc2 ([Figure 8---figure supplement 1A,B](#fig8s1){ref-type="fig"}). We found that Vax1(WF/SR) barely penetrated RGC axons and induced RGC axonal growth less efficiently than WT Vax1 ([Figure 8---figure supplement 1C,D](#fig8s1){ref-type="fig"}). These results suggest that Vax1-induced RGC axonal growth requires cell penetration.

To determine which cytoplasmic events Vax1 might affect, we identified cytoplasmic Vax1-interacting proteins by MALDI-TOF (matrix-assisted laser desorption/ionization-time of flight) mass spectrometry ([Figure 8A](#fig8){ref-type="fig"}). Interestingly, a majority of proteins isolated by Vax1-affinity purification were related to protein synthesis, including ribosomal proteins (RPs) L11, L23A, L26, S14, and S16; translation regulators, such as eukaryotic translation initiation factor (eIF) 3B and 3C; and the chaperone HSPA1A (heat shock 70-kDa protein 1A). These data suggest that Vax1 might act in RGC axons by modulating protein synthesis, a mechanism similar to that by which cytoplasmic En2 controls RGC axonal growth ([@bib5]; [@bib49]). To confirm this, we tested the effects of Vax1 on protein synthesis in RGC axons by quantifying the newly synthesized proteins, measuring the fluorescence intensity of incorporated bioorthogonal noncanonical amino acid azidohomoalanine (AHA), labeled with Alexa Fluor 488 by click chemistry ([@bib10]). Treatment with Vax1-His induced a remarkable increase in the fluorescence intensities of AHA-Fluor 488-labeled proteins in RGC axons ([Figure 8B](#fig8){ref-type="fig"}, middle column), whereas the Vax1(WF/SR)-His had no effect on protein synthesis ([Figure 8B](#fig8){ref-type="fig"}, right column), indicating that intracellular Vax1 stimulated protein synthesis.10.7554/eLife.02671.022Figure 8.Imported Vax1 induces RGC axonal growth by stimulating local protein synthesis.(**A**) GST and GST-Vax1 protein complexes were affinity purified from cytoplasmic fractions of HEK293T cells overexpressing GST and GST-Vax1, respectively (see 'Materials and methods' for details). Complexes were then analyzed by SDS-PAGE on 10% gels and subsequent silver staining to detect proteins specifically enriched in GST-Vax1 complexes. The identities of protein bands, shown to the right of the gel photograph, were determined by MALDI-TOF mass spectrometry. Vax1-FL, full-length Vax1; Vax1-N\*, Vax1 N-terminal fragment. (**B**) E13.5 mouse retinal explants were cultured for 24 hr before changing to medium containing Vax1-His (100 ng/ml) or Vax1(WF/SR)-His (100 ng/ml) for an additional 16 hr-incubation. The explants were further incubated for 6 hr after addition of the bioorthogonal noncanonical amino acid AHA (L-azidohomoalanine). Newly synthesized proteins incorporating these noncanonical amino acids were labeled with Alexa Fluor 488-alkyne by click chemistry ([@bib10]), and the rates of protein synthesis in RGC axons (middle row) and explant cell body (bottom) were assessed by measuring the fluorescence intensities of AHA-Alexa Fluor 488-labeled proteins (see 'Materials and methods' for details). Scale bars: 500 μm (top) and 100 μm (bottom). (**C**) The influence of nuclear events in Vax1-induced RGC axon growth was excluded by isolating axons from the cell body before treatment with Vax1 proteins (100 ng/ml) for 6 hr. Arrowheads indicate the area magnified in each inset. Scale bars: 500 μm. (**D**) Relative AHA-Alexa488 fluorescence intensities in cell body-free axons were measured using ImageJ software and are shown graphically. Error bars denote SDs. (**E**) Relative distances that RGC axons grew during this 6-hr incubation period are presented graphically. The values in the graph are averages of fold ratios compared with those of untreated samples. Scores on top of the graph columns in (**D**) and (**E**) are number of axons analyzed (\*\*p \< 0.001; ANOVA). Results were obtained from two independent experiments. Numbers of explants analyzed: untreated, n = 4; Vax1, n = 5; Vax1(WF/SR), n = 4.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.022](10.7554/eLife.02671.022)10.7554/eLife.02671.023Figure 8---figure supplement 1.Biophysical properties of Vax1(WF/SR) mutant protein.(**A**) Trp and Phe (WF) at amino acid residues 147 and 148 of mouse Vax1, which are homologous to the critical residues of the cell-penetrating region of the Antp (antennapedia) homeodomain ([@bib19]), were mutated to Ser--Arg (SR) in Vax1(WF/SR). Vax1 and Vax1(WF/SR) interactions with GFP-Sdc2 were assessed by immunoprecipitating cell lysates with α-Vax1 and subsequent Western blotting with α-GFP. Successful expression of Vax1 and GFP-Sdc2 was also assessed by Western blotting of cell lysates. (**B**) COS7 cells were incubated for 3 hr with growth medium (S3 fraction) from HEK293T cells overexpressing Vax1-V5 or Vax1(WF/SR)-V5. Vax1 protein at the intact cell surface was detected with rabbit α-Vax1 (green), whereas Vax1 protein inside cells and at the cell surface of fixed cells was labeled with mouse α-V5 (red). After incubating with Alexa 488-conjugated α-mouse IgG and Cy3-conjugated α-rabbit IgG, the distribution of cell surface and intracellular Vax1 was analyzed by confocal microscopy. Scale bars: 20 μm. (**C**) The importance of cell penetration of Vax1 for RGC axonal growth was investigated by co-culturing mouse retinal explants (NR) with COS7 cells overexpressing WT Vax1 or Vax1(WF/SR) mutant for 48 hr. The explants were then stained with rabbit α-Vax1 (green) and mouse α-NF160 (red). Scale bars: 500 μm (top) and 200 μm (bottom). (**D**) Relative axon content in each angle segment was analyzed as described in 'Materials and methods' and is shown graphically. The values in the graph are averages, and error bars denote standard deviations (SD). Results were obtained from three independent experiments. The scores under *y*-axis labels are the number of explants analyzed. *p*-values are between 0.001 and 0.005 (ANOVA).**DOI:** [http://dx.doi.org/10.7554/eLife.02671.023](10.7554/eLife.02671.023)

In contrast to its significant induction of protein synthesis in axons, Vax1-His-induced effects on AHA-Fluor 488 fluorescence intensities in retinal cell bodies were not notably different from those of Vax1(WF/SR)-His or the 6X-His ([Figure 8B](#fig8){ref-type="fig"}, bottom row). Similarly, Vax1 failed to stimulate general translation in the cultured cell-lines and purified polysomes in vitro (data not shown). In contrast, isolated retinal axons from the cell body still responded to Vax1 as efficiently as those that projected from intact retinal explants ([Figure 8C,D](#fig8){ref-type="fig"}). Taken together, these results suggest that Vax1 stimulates RGC axon growth by stimulating local translation of specific mRNA in the axon rather than by modulating gene expression in the cell body.

Imported Vax1 promotes the access of RGC axons to the midline {#s2-9}
-------------------------------------------------------------

We further investigated whether extracellular Vax1 could restore RGC axon growth towards the midline in *Vax1*^*−/−*^ mice by re-supplying Vax1 protein to the vHT extracellular space. In contrast to the lack of RGC axon access to the vHT observed in *Vax1*^*−/−*^ mouse embryos, remarkable numbers of RGC axons were detectable in the vHT of *Vax1*^*−/−*^ mouse embryos implanted with collagen gels that released recombinant Vax1-His ([Figure 9A](#fig9){ref-type="fig"}, top rows of left two columns, B). Remarkable number of RGC axons were able to grow to the source of extracellular Vax1 protein (i.e., the third ventricle), although they failed to restore the OC. In contrast, implantation of collagen gels that released cell-penetration--defective Vax1(WF/SR)-His did not induce the regrowth of RGC axons ([Figure 9A, \[third column\], B](#fig9){ref-type="fig"}). Implanted recombinant Vax1-His was detectable in RGC axons, whereas Vax1(WF/SR)-His was not, suggesting that the implanted Vax1 stimulated RGC axon growth by penetrating into the axoplasm.10.7554/eLife.02671.024Figure 9.RGC axons re-grow in Vax1-implanted, *Vax1*^*−/−*^ mouse brains.(**A**) The third ventricles of E13.5 *Vax1*^*−/−*^ mouse-head slabs were implanted with collagen gels mixed with 6X-His peptide (4.78 μg/ml; 5.69 nmol), Vax1-His (200 μg/ml; 5.69 nmol), or Vax1(WF/SR)-His (200 μg/ml; 5.69 nmol) and incubated for 12 hr (see diagram in [Figure 5D](#fig5){ref-type="fig"} and 'Materials and methods' for details). *Vax1*^*−/−*^ mouse-head slabs were also implanted with collagen gels mixed with Robo1-Fc fragment (1 μg/ml; 12.35 pmol; R&D Systems, Minneapolis, MN, USA) in the presence of 6X-His peptide (4.78 μg/ml; 5.69 nmol) or Vax1-His (200 μg/ml; 5.69 nmol) and incubated for 12 hr. The fluorescence images of horizontal sections of head slabs were obtained using an Olympus FV1000 confocal microscopy equipped with a transmitted light detector (top row). The same embryonic sections were further stained with rabbit anti-Vax1 (green) and mouse anti-NF160 (red) antibodies (bottom row). (**B**) Fluorescence intensities of NF160 immunostains in the boxed areas in (**A**) were measured using ImageJ software and are presented graphically. The values are intensities expressed relative to rb-IgG-treated samples, and error bars denote SDs (\*\*p \< 0.001; ANOVA). Numbers on top of the graph columns are head-slab preparations.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.024](10.7554/eLife.02671.024)10.7554/eLife.02671.025Figure 9---figure supplement 1.vHT-secreted Silt inhibits RGC axon growth.(**A**) E13.5 WT retinal explants were co-incubated with E13.5 *Vax1-ko* vHT explants for 24 hr in the presence (bottom) or absence (top) of Robo1-Fc (100 ng/ml). Dark field images of the explants were taken before (0 hr; left column) and after (24 hr; center column) the incubation. The explants were then fixed for immunostaining with mouse anti-NF160 antibody (red). Immunostaining images of dotted boxed areas in the center column are shown in the right column. DAPI, nuclear counter staining. Scale bars denote 500 μm. (**B**) The angular distribution of RGC axons was measured by counting axon marker NF160 immunostaining image pixels (axon counts) as described in 'Materials and methods' and presented graphically. +, forward direction angle segment; 0, neutral direction angle segments; −, reverse direction angle segment. The values in the bar are averages, and error bars denote SDs. Numbers under y-axis labels are the number of explants analyzed. *p*-values determined by ANOVA test are \<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.025](10.7554/eLife.02671.025)10.7554/eLife.02671.026Figure 9---figure supplement 2.Reciprocal antagonism between Vax1 and Slit2 in vitro.(**A**) E13.5 mouse retinal explants were cultured for 24 hr prior to treatment with Slit2-His (10 ng/ml; R&D Systems) for 24 hr in the absence (left) of Vax1-His or in the presence of 10 ng/ml (middle) or 100 ng/ml (right) of Vax1-His (top row). In reciprocal experiments, explants were treated with Vax1-His (10 ng/ml) for 24 hr in the absence (left) of Slit2-His or the presence of 10 ng/ml (middle) or 100 ng/ml (right) Slit2-His (bottom row). (**B**) The changes in RGC axon length during the last 24 hr are shown graphically. Error bars denote SD and the scores on top of the graph columns are the number of axons analyzed. Number of explants analyzed: untreated, n = 22; Vax1 (10 ng/ml), n = 10; Vax1 (100 ng/ml), n = 9; Slit2 (10 ng/ml), n = 5; Slit2 (100 ng/ml), n = 5; Vax1 (10 ng/ml) + Slit2 (10 ng/ml), n = 7; Vax1 (10 ng/ml) + Slit2 (100 ng/ml), n = 6; Vax1 (10 ng/ml) + Slit2 (10 ng/ml), n = 13; and Vax1 (100 ng/ml) + Slit2 (10 ng/ml), n = 7. Results were obtained from four (for the first two) or three (for the rest) independent experiments. (**C**) Vax1-His and Slit2-His added to the retinal explants were detected by immunostaining with rabbit α-Vax1 (green) and mouse α-Slit2 (red). Scale bars: 20 μm. Fluorescent intensities Vax1 and Slit2 immunostaining images were measured by ImageJ software and shown graphically. Scores on top of the columns are number of areas analyzed. Number of explants analyzed for immunostainings are same as (**B**).**DOI:** [http://dx.doi.org/10.7554/eLife.02671.026](10.7554/eLife.02671.026)

It has been suggested that the avoidance of RGC axons in *Vax1*^*−/−*^ mouse vHT might result from high concentrations of Slit protein in the ventral-lateral diencephalon ([@bib2]). In support of this, the growth of RGC axons towards *Vax1*^*−/−*^ vHT explants were partly recovered by sequestering extracellular Slit protein using an Fc-fused extracellular fragment of the Slit receptor Robo1 (Robo1-Fc) ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). Thus, we further investigated the roles of Slit in RGC axon avoidance in *Vax1*^*−/−*^ mouse embryos using Robo1-Fc. The growth of RGC axons into the vHT was partially rescued by implanting a Robo1-Fc--releasing collagen gel into the third ventricle, an effect that was further enhanced by implantation of gels co-releasing Vax1-His and Robo1-Fc ([Figure 9A](#fig9){ref-type="fig"}, two right columns, B).

Discussion {#s3}
==========

RGC axonal projection to the OC is often compared to the spinal commissural axonal projection toward the floor plate (FP). Spinal commissural axons are prevented from prematurely entering the midline by Slit1 expressed in the medial spinal cord and grow in the ventral direction ([@bib42]). In much the same way, Slit1 in the preoptic area and ventral-lateral diencephalon prevents RGC axons from accessing the brain anywhere but at the vHT to form the OC ([@bib13]; [@bib34]). The spinal commissural axons sense attractive cues, such as netrin and Shh, secreted from the FP ([@bib42]; [@bib7]). The attractive netrin and Shh signals are expected to compete with the co-existing repulsive signal of Slit2, which can be accumulated locally by HSPGs, including α-dystroglycan, at the ventral FP (vFP), to determine the directionality of spinal commissural axon growth cones ([@bib27]; [@bib48]). RGC-expressed HSPGs were also reported to play roles as co-receptors for netrin and Slit ([@bib18]; [@bib16]; [@bib33]; [@bib31]), suggesting a similar HSPG-based antagonistic regulation of RGC axon growth. However, both netrin and Shh are dispensable with respect to attracting RGC axons toward the vHT and instead function as repulsive cues for RGC axons ([@bib9]; [@bib36]). In this study, we propose vHT-secreted Vax1 as a RGC axon growth factor that is analogous to vFP-secreted netrin and Shh. This unconventional axon growth factor also utilizes HSPGs for anchoring to RGC axons ([Figure 7](#fig7){ref-type="fig"}) and could compete with Slit for HSPGs binding in vitro ([Figure 9---figure supplement 2](#fig9s2){ref-type="fig"}). However, it is unclear whether this competition is valid in physiological conditions because Slit does not inhibit RGC axon growth toward the vHT midline ([@bib13]; [@bib34]). Moreover, cell penetration-defective Vax1(WF/SR) mutant could not induce RGC axon growth in vivo as well as in vitro, despite of its capability of HSPG binding ([Figures 8 and 9](#fig8 fig9){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). It suggests that HSPG binding of Vax1 is not sufficient to induce RGC axon growth but local protein synthesis induced by internalized Vax1 is necessary. Collectively, we propose a hypothetical model that Vax1 promotes RGC axon growth towards the vHT midline by directly targeting mRNA in the axons rather than by serving for a conventional axon guidance molecule that binds specific receptors and triggers on intracellular signaling cascades ([Figure 10](#fig10){ref-type="fig"}). Identification of axonal target mRNA awaits future investigations.10.7554/eLife.02671.027Figure 10.Model depicting Vax1 functions as a secreted retinal axon growth factor.Vax1 is expressed in radial glia and NPCs of the vHT as well as the OS APCs (**A**) and secreted to the extracellular space (**B**). RGC axons that grow in the OS capture APC-secreted Vax1 by HSPGs, resulting in an increase in Vax1 concentration at RGC axons for subsequent penetration and local activation of translation in the axon (**B**). The imported Vax1 in RGC axoplasm not only promotes axonal growth towards the vHT, but it also enhances fasciculation of RGC axons. This axon growth stimulatory activity of Vax1 supports sustained RGC axon growth to the vHT midline after the axons were avoided from progressing to dorsal diencephalon, which expresses high concentration of Slit repulsive axon guidance cue (**C**, top). Therefore, RGC axons stop at the lateral wall of *Vax1-ko* mouse diencephalon and fail to access the midline (**C**, bottom). At the vHT midline, RGC axon guidance cues, including VEGF164, NrCAM, and ephrinB2, determine the directionalities of RGC axon growth cones by acting their specific receptors (**D**). Vax1 does not likely determine the directionalities of RGC axon growth cone at the midline but does promote the growth of the RGC axon shaft as well as the growth cone regardless of their original positions in the retina.**DOI:** [http://dx.doi.org/10.7554/eLife.02671.027](10.7554/eLife.02671.027)

Translation-dependent, but transcription-independent, RGC axon guidance by a secreted transcription factor has also been reported for En2, which regulates RGC growth cone turning by increasing the expression of mitochondrial proteins involved in elevating the local ATP, which potentiates ephrin A5 signaling ([@bib5]; [@bib43]; [@bib49]). Since Vax1 and En2 share a homologous homeodomain, Vax1 could function in a similar manner by cooperating with attractive RGC axon guidance cues, such as VEGF164 and NrCAM ([@bib46]; [@bib12]; [@bib23]), and by modulating mitochondrial activity. Conversely, En2 could also use HSPGs to bind target axons and fine-tune their selective growth.

In their use of HSPGs as docking sites for RGC axons, Vax1 can be compared to Otx2 that binds specifically to CSPGs of the perineuronal net surrounding parvalbumin (PV) neurons in the visual cortex ([@bib3]; [@bib28]). The differential affinities of Vax1 and Otx2 for HS and CS might be related to their different homeodomains. Among homeodomain proteins proven to exhibit transfer, Vax1 possesses an antennapedia class homeodomain homologous to that of Emx2 and En2, whereas Otx2 shares a paired class homeodomain similar to that of Pax6 (paired box 6) ([@bib6]; [@bib40]). One intriguing possibility that has not yet been explored is that these secreted homeodomain proteins share the property of preferential binding to HS and CS; however, it is at least as likely that intercellular transfer of homeodomain proteins are target-selective events.

Vax2 was not as effectively secreted from COS7 cells as Vax1 ([Figure 2](#fig2){ref-type="fig"}), despite sharing an identical homeodomain with Vax1. This suggests that secretion of Vax1 is not solely mediated by the homeodomain but is also dependent on a three-dimensional structure that supports the secretion property of the homeodomain. Unlike Vax1, Vax2 undergoes a specific phosphorylation that results in its cytoplasmic retention ([@bib22]). Phosphorylation of En2 inhibits its secretion ([@bib26]), suggesting that the phosphorylation might change the structure of these proteins in such a way that it interferes with homeodomain recognition by secretion regulators. However, phosphorylation-defective Vax1(S170A) was still unable to be secreted from COS7 cells (data not shown). Instead, Vax2 could be secreted from different types of cells, where Vax2 might form three-dimensional structures that can be recognizable by secretion machineries (*Lee et al., unpublished data*). The results suggest that the secretion of homeodomain proteins is a cell context-dependent event.

Multiple midline-crossing defects, including agenesis of the corpus callosum, anterior commissure, and hippocampal commissure, are observed in *Vax1-*deficient mice and homozygous *VAX1* mutant human patients ([@bib2]; [@bib38]). However, the molecular functions of Vax1 in the development of these structures remain unknown. In this study, we show that Vax1-induced RGC axonal growth is independent of its transcription factor activity ([Figures 2A and 3C](#fig2 fig3){ref-type="fig"}). Instead, Vax1 acts as a regulator of translation after penetrating into RGC axons ([Figure 8](#fig8){ref-type="fig"}). Although we cannot rule out Vax1 functions as a transcription factor in the development of those commissures, our results suggest a potential role of secreted Vax1 in the growth of cortical axons (*Min et al., unpublished data*). Whether axonal growth of these commissural axons in the mammalian forebrain also requires local protein synthesis triggered by Vax1 protein secreted from cells located in other midline structures, such as the ventral-medial telencephalon and the septum, is a question that warrants further investigation.

Materials and methods {#s4}
=====================

Mice and explant culture {#s4-1}
------------------------

*Vax1* knock-out (*Vax1*^*−/−*^) and *Vax1* knock-in (*Vax1*^*lacZ/lacZ*^) mice were reported previously ([@bib2]; [@bib14]). Retinal and vHT explants were cultured as described previously ([@bib37]). Briefly, retinal or vHT explants were added to a collagen mixture and positioned on plates coated with poly-L-lysine (10 μg/ml) and laminin (10 μg/ml). The explants were then incubated at 37°C for 1 hr to allow gelling before adding Neurobasal medium containing B27 supplement (Invitrogen, Carlsbad, CA, USA). COS7 cell droplets (10^5^ cells/droplet) were also prepared using the same procedures. The explants were cultured alone or co-cultured with vHT or COS7 explants for 48 hr before treating with proteins and antibodies.

For time-lapse recording of retinal axon growth, mouse retinal explants were treated with FITC-labeled 6X-His peptide (100 ng/ml, 500 ng/ml) or Vax1-His protein (500 ng/ml) for 24 hr and photographed every 15 min using a Zeiss Axio Observer Z1 inverted microscope. The explants were washed twice with phosphate-buffered saline (PBS) prior to incubation with rabbit anti-Vax1 polyclonal antibody (α-Vax1; 1:100) for 30 min to detect Vax1-His located on the cell surface. The explants were then washed with PBS and fixed in 4% paraformaldehyde (PFA)/PBS for subsequent immunostaining procedures to detect total Vax1-His protein inside and outside of cells.

For slab embryo culture with collagen gel implantation, E13.5 mouse embryos were moved onto culture slide chambers containing collagen mixture, positioning the dorsal part on top, after dissecting out the dorsal half of the brain and lower part of the mouth. Droplets of collagen solution mixed with pre-immune IgG (1 μg/ml), α-Vax1 (1 μg/ml), 6X-His peptide (4.78 μg/ml), or Vax1-His (200 μg/ml) protein were then delivered into the third ventricle of the slab embryos. The embryos were then filled with culture medium and incubated for 12 hr at 37°C in a humidified atmosphere supplemented with 7% CO~2~. The embryos were fixed in 4% PFA/PBS for subsequent freezing in OCT (optimal cutting temperature) medium. RGC axon growth at the vHT was monitored along the horizontal axis of slide-mounted embryonic brain sections under an Olympus BX-71 microscope. The slides were then stained with appropriate antibodies and examined under an Olympus FV1000 confocal microscope to detect the penetration of implanted Vax1 protein into RGC axons.

Retinal axon count {#s4-2}
------------------

Relative axon counts (combined values of numbers and lengths of axons) of retinal explants were obtained by measuring NF160-fluorescent pixels in images of retinal axons using the ImageJ software. Relative axon counts of retinal explants co-cultured with the vHT explants or COS7 cell aggregates were obtained along three angle segments: forward (+), neutral (0), and reverse (−). A clockwise angle from a line connecting two centers of explants was obtained and classified as forward direction (+) if it was between 0° and 60° or between 301° and 360°; neutral direction (0) if it was between 61° and 120° or between 241° and 300°; and reverse direction (−) if it was between 121° and 240° ([Figures 2B and 5B](#fig2 fig5){ref-type="fig"}). Relative axon counts in each angle segment were then obtained by comparing the pixel counts of NF160 immunofluorescence in RGC axons of the explants in each angle segment.

Antibodies {#s4-3}
----------

α-Vax1 and α-Vax2 were produced as reported previously ([@bib29]). Commercially available antibodies against the following proteins were used: mouse anti-Myc (Santa Cruz Biotechnology, Dallas, TX, USA), mouse anti-GFP (Santa Cruz Biotechnology, Dallas, TX, USA), mouse anti-tubulin β-III (Tuj1; Covance, Princeton, NJ, USA), goat anti-Sox2 (Santa Cruz Biotechnology, Dallas, TX, USA), mouse anti-Nestin (RC2; Millipore, Billerica, MA, USA), mouse anti-β-galactosidase (Developmental Studies Hybridoma Bank, DSHB), mouse anti-NF160 (Developmental Studies Hybridoma Bank \[DSHB\], Iowa City, IA, USA), goat anti-Sdc2 (Santa Cruz Biotechnology, Dallas, TX, USA), goat anti-Sdc3 (Santa Cruz Biotechnology (Dallas, TX, USA), for immunohistochemistry), rabbit anti-Sdc3 (Abcam (UK), for Western blot), rabbit anti-Glp1 (Santa Cruz Biotechnology, Dallas, TX, USA), and rabbit anti-Pax2 (Invitrogen, Carlsbad, CA, USA) antibodies.

Immunohistochemistry {#s4-4}
--------------------

The heads of embryonic mice were fixed in 4% PFA/PBS at 4°C for 2--16 hr, depending on the protein to be detected, and then incubated in a 20% sucrose/PBS solution at 4°C for 16 hr before embedding in OCT medium for freezing. Sections of frozen tissue were incubated for 1 hr in a blocking solution containing 0.2% Triton X-100, 5% normal donkey serum, and 2% bovine serum albumen (BSA) in PBS. Sections were first incubated with the indicated primary antibodies in blocking solution without 0.2% Triton X-100 at 4°C for 16 hr and then with the appropriate Alexa488-, Cy3-, or Cy5-conjugated secondary antibody. Immunofluorescence was subsequently analyzed using Olympus FV1000 and Zeiss LSM710 confocal microscopes.

Isolation and detection of extracellular proteins in growth media and CSF {#s4-5}
-------------------------------------------------------------------------

Growth medium or CSF from the lateral ventricle of E14.5 mice was centrifuged twice at 500×*g* for 10 min and then twice at 2000×*g* for 15 min to obtain supernatant (S3) fractions. The S3 fractions were then mixed with an equal volume of 3 M trichloroacetic acid (TCA) solution to precipitate the macromolecules. The TCA precipitates were washed twice with 100% acetone, air-dried pellets, and dissolved in 2×-sodium dodecyl sulfate (SDS) sample buffer for SDS-PAGE (polyacrylamide gel electrophoresis) analysis.

*Drosophila* lines and whole-mount immunostaining {#s4-6}
-------------------------------------------------

*Ptc-Gal4, UAS-DsRed, UAS-Sdc, UAS-Dlp*, and *sdc*^*23*^ flies were obtained from the Bloomington stock center, IN, USA. The UAS-*Vax1-EGFP* fly was generated by injection of pUAS-Vax1-EGFP constructed by cloning mouse Vax1 cDNA into the pUAST-EGFP vector. Third-instar larvae of *Ptc-Gal4\>UAS-Vax1-EGFP,UAS-DsRed;+* were obtained from a cross of the *Ptc-Gal4\>UAS-DsRed;TM6B* fly with a *UAS-Vax1-EGFP* fly.

After fixing larval wing imaginal discs with 4% PFA/PBS for 30 min, the *Ptc-Gal4*-induced green fluorescence signals from EGFP and Vax1-EGFP proteins were compared with red fluorescence signals from DsRed proteins by confocal microscopy (Olympus FV1000).

Co-immunoprecipitation {#s4-7}
----------------------

HEK293T cells and E14.5 mouse optic nerves were lysed in a buffer consisting of 10 mM Tris--HCl (pH 7.4), 200 mM NaCl, 1% Triton X-100, and 1% NP-40. Cell lysates were centrifuged at 12000×*g* for 10 min at 4°C. The supernatants were collected and incubated with the indicated antibodies at 4°C for 16 hr; then, protein A-agarose beads were added and incubation was continued at 4°C for 1 hr. After washing the immune complexes five times with lysis buffer, proteins were eluted with 2× SDS sample buffer. Samples were then analyzed by SDS-PAGE and Western blotting.

GST-affinity purification of Vax1-interacting proteins {#s4-8}
------------------------------------------------------

HEK293T cells transfected with pEBG or pEBG-Vax1 were lysed with a buffer consisting of 10 mM Tris--HCl (pH 7.4), 200 mM NaCl, and 1% NP-40. Cell lysates were centrifuged at 12000×*g* for 10 min at 4°C. The supernatants were collected and incubated with glutathione Sepharose 4B resin (GE Healthcare) at 4°C for 1 hr. After washing five times with lysis buffer, proteins were eluted with 2× SDS sample buffer and samples were analyzed by SDS-PAGE on 10% gels. Gels were stained using Silver Stain Kit for Mass Spectrometry (Pierce) to isolate bands for MALDI-TOF mass spectrometry analysis at the Korea Basic Science Institute (KBSI), Daejeon, South Korea.

Click chemistry for labeling newly synthesized proteins {#s4-9}
-------------------------------------------------------

Explant culture media were replaced with methionine-free media, 30 min prior to the addition of 50 μM L-azidohomoalanine (AHA, Invitrogen (Carlsbad, CA, USA)). After 6 hr, retinal explants were washed twice with PBS containing 1% fetal bovine serum (FBS) and then 30 μM DIBO-Alexa Fluor 488 (Invitrogen, Carlsbad, CA, USA) in PBS containing 1% FBS was added. The explants were then incubated at room temperature in the dark for 1 hr. After washing four times in PBS containing 1% FBS, retinal explants were fixed with 4% PFA in PBS for 15 min at room temperature for subsequent detection of the fluorescence of proteins incorporating AHA-Alexa Fluor 488.
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Thank you for sending your work entitled "Regulation of retinal axon growth by secreted Vax1 homeodomain protein" for consideration at *eLife*. Your article has been favorably evaluated by a Senior editor and 3 reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing editor, Marianne Bronner, and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

This is an interesting study that identifies a somewhat unexpected mechanism by which the transcription factor Vax1 regulates retinal ganglion cell (RGC) axon growth. The authors report that despite the lack of Vax1 mRNA expression in RGCs, they detect Vax1 protein in RGCs in vivo. The authors utilize in vitro experiments to demonstrate that Vax1 functions in a non-cell autonomous manner and, similar to other homeobox transcription factors, Vax1 can be secreted. The authors go on to show that similar to En-2, Vax1 is internalized by RGC axons, where it stimulates axonal outgrowth in a transcription-independent manner by upregulating axonal translation. The authors also perform a screen in drosophila for molecules that mediate the intercellular transfer of Vax1 and identify HSPGs as critical for Vax1 function. Finally, the authors perform in vivo rescue experiments in Vax1 knockout mice to show that wildtype Vax1 in the 3rd ventricle can increase RGC growth, whereas a mutant version of Vax1 that cannot penetrate RGC axons fails to rescue. Taken together, these data lead the authors to propose a model in which Vax1, secreted from external sources such as the radial glia in the optic chiasm, can penetrate RGCs in an HSPG dependent manner to upregulate local translation in axons to positively regulate their outgrowth.

The identification of homeodomain transcription factors as "axon guidance molecules" is interesting. The present study is not the first report of this phenomenon, but does provide a solid basis for making this claim.

Substantive concerns:

1\) The references to other studies are deficient (missing or improper citation/interpretation) and the text should be edited for proper English usage. For example, the authors should cite papers regarding the idea that HSPGs are involved in axon guidance, and particularly at the optic chiasm, since this is not a new concept. For example: [@bib8], J Comp Neurol 436: 236; [@bib35], J Neurosci.26:6911; Conway et al., 2011, J Neurosci 31: 1955; Wilson and Stoeckli, 2013, Neuron 79:478; Sánchez-Arrones et al., 2013, J Neurosci 33:8596; Fabre et al., 2010, J Neurosci 30:266 and Yam and Charron, Curr Op Neurobiol 2013).

2\) Although the authors show that the chiasm appears normal by RC2 staining, they should confirm that the expression of known chiasm localized cues (Vegf, ephrinB1, NrCAM) is normal. Similarly, there is no information on localization of HSPGs on RGCs nor is there any proposal/analysis on the fate of HSPGs after Vax1 binds: are they also internalized? If not, are they cleaved once bound to Vax1? These points should be discussed. A large number of HSPG binding proteins have been identified (e.g. FGF2, slit2, Semas, ephrins, syndecans, glypicans, etc). For all these cues HSPGs function as co-receptors for a transmembrane spanning signaling receptor. The authors should discuss this possibility and whether there is data for co-localization of these on RGCs.

3\) The explants tested were taken from dorsal retina, at E13, when a few cells project ipsilaterally but ultimately disappear. The ventrotemporal retina gives rise to the permanent ipsilateral component after E14. Have the authors analyzed expression of syndecan or glypican in the "ipsi" retina and how Vax1-HSPG interactions underlie ipsi axon midline avoidance? This could be addressed by comparing ventrotemporal versus dorsotemporal retina.

4\) The authors propose that vax1 overrides Robo/slit repulsion. Is slit repulsion of cultured RGC axons reduced (blocked) in the presence of recombinant vax1? Slits are thought to inhibit RGC axons from straying (defasciculating) from the main bundles at the chiasm, in an "inhibition-surround" mechanism, not as an inhibitory molecule at the crossing point (see Erskine et al., J Neurosci 2000, 20:4975; [@bib34] Neuron 33:219). The authors placed Vax-1-containing cells in the third ventricle above the chiasm in an isolated prep, showing that growth was enhanced, and application of Fc-Robo3 also enhanced RGC axon growth (together growth was further enhanced). While this experiment argues for Slit involvement in this preparation, it cannot relate to guidance in vivo because Robo3 is not expressed in the mouse retina (see above references and Thompson et al., 2006, J Neurosci 26:8092). Further, there should be axon extension in the control preparation in [Figure 9A](#fig9){ref-type="fig"}. Finally, the model posed in [Figure 9](#fig9){ref-type="fig"} is misleading: how would the Vax1-HSPG interaction act on Slit inhibition leading to action of molecules important for contralateral crossing (e.g., VEGF164, NrCAM, and Semaphorin6D, latter, erroneously indicated for ipsilateral growth)?

5\) The authors show that in contrast to Vax1, Vax2 is not secreted and does not bind to HSPGs ([Figure 2C](#fig2){ref-type="fig"}, [Figure 7--figure supplement 1B](#fig7s1){ref-type="fig"}). This is somewhat surprising, since the domains that regulate secretion of homeodomain transcription factors are typically within the homeodomain region, which is highly conserved between Vax1 and Vax2. Have the authors attempted to identify the specific domains required for secretion and HSPG binding that differ between Vax1 and Vax2? The authors should test whether the addition of exogenous Vax2 can bind to RGCs and promote their outgrowth using assays like those used in [Figure 3](#fig3){ref-type="fig"}.

6\) Immuno-EM studies show that vax1 is localized to the axonal surface of RGCs and also found in endocytosed vesicles. To participate in local translation, vax1 likely needs to be in the cytoplasm not inside vesicles?

7\) In the co-culture assays in [Figure 1C-D](#fig1){ref-type="fig"}, WT retinal explants cultured with Vax1-/- vHT not only shows no attraction, but appears to show active repulsion. This may be due to the secretion of Slit from the explants, which should be tested by examining whether addition of Robo-Fc (similar to [Figure 9A](#fig9){ref-type="fig"}) inhibits this repulsion. With respect to Vax localization and uptake, [Figure 4C and D](#fig4){ref-type="fig"} shows immunostaining for Vax1 protein on axons and in D in the immune-EM figures, only on the axon surface; this is puzzling as the authors\' model is that Vax1 is internalized and thus one would expect Vax1 to be in the cytoplasm of the cell *--* axon or cell body.

8\) In [Figure 9--figure supplement 1](#fig9s1){ref-type="fig"}, the authors show that Vax1 and Slit are mutually antagonistic with respect to axon outgrowth. In the images (S9C), it appears that the addition of Slit blocks Vax1 localization in the axons to some extent. This should be examined in biochemical assays by assessing how the presence of Slit or Vax1 affects the other\'s binding to HSPGs (similar to assays in [Figure 7--figure supplement 1A](#fig7s1){ref-type="fig"}). Alternatively, it would be informative to know whether addition of Slit inhibits Vax1 induction of axonal translation ([Figure 8B](#fig8){ref-type="fig"}).

9\) It is not clear whether soluble vax1 primarily exerts its function as a growth promoting factor (chemotrophic, i.e. [Figure 5](#fig5){ref-type="fig"}) or steering function (chemotropic, i.e. [Figure 1](#fig1){ref-type="fig"}) or both? Can the effects of vax1 secreted from COS7 cells be blocked in the presence of the anti-vax1 serum?

10\) Blocking of translation with anisomycin may affect neurite outgrowth in a vax1-independent manner. Additional controls are needed to show that in the presence of a growth promoting cue (other than vax1) blocking of translation with anisomycin does not influence outgrowth rate.

\[Editors' note: the reviewers had the following concerns after re-review, which were addressed before acceptance.\]

We are very sorry to report that, after a second round of review, the changes you made were not deemed to sufficient to render your paper acceptable for publication in *eLife* at this point. We hope that the detailed comments of the reviewers will help you in improving the paper.

Reviewer 1:

The authors have addressed the reviewers\' comments, performing additional experiments and presenting new micrographs and other data. Nonetheless, there are still some amendments needed to clarify the model and data.

1\) The reader must still work very hard in understanding how Vax acts to enhance axon growth.

a\) One problem is that the authors "tell the story" in different ways, sometimes completely and in other places, leaving out one of the elements.

In the rebuttal: "Our overall hypothetical model is that HSPGs capture secreted Vax1 and release it to the plasma membrane for further cytoplasmic penetration."

"This unconventional axon growth factor also utilizes HSPGs for anchoring to RGC axons and antagonizes Slit effects on RGC axon binding and growth ([Figure 9--figure supplement 1](#fig9s1){ref-type="fig"})."

In the rebuttal, second paragraph: "We modified our model (revised [Figure 9C](#fig9){ref-type="fig"}) regarding Vax1 and Slit competition for HSPGs in RGC \... in this competition, vHT-enriched Vax1 displaces Slit, which is bound to HSPGs in RGC axons at the lateral diencephalon, and promotes further growth toward the midline where RGC axons meet pathway determinants (e.g., VEGF164", etc).

b\) The all-important schema graphically illustrating the steps, in [Figure 9](#fig9){ref-type="fig"}, does not clearly illustrate what the authors intend to describe. From the graphic, one cannot intuit the process of Vax attachment to HSPGs on RGC surface, then enhancement of growth during midline crossing.

The various interactions might be broken into steps (attachment of Vax to HSPGs, then internalization, followed by retrograde transport to the cell body and/or action locally in the growth cone, finally axon extension)?

The growth cone should be enlarged, and perhaps use a different icon for the guidance molecules.

Sema6D is not a repellant for ipsilateral axons; it belongs with NrCAM on the contralateral axons.

2\) In the rebuttal, major point 7: The co-culture assays with knockout vHT and Robo1-Fc should be included in the manuscript; these are important data and should not be hidden only for reviewers\' inspection.

3\) Response to minor point 7 is a little dismissive and unsatisfactory. The DiI labeling in the images of cryosectioned DiI is so fuzzy/overexposed/difficult to see clearly, that they would be better off just using the cytoarchitecture to determine the location of the RGC axon bundle. As is, the DiI quality distracts from the overall point of the figure. If the immunostaining is more important for them to show, as they indicate, they should focus on that and orient things based on cytoarchitecture, which should be sufficient to locate the axon bundles, and just leave out the DiI altogether.

4\) In minor point 10 re: [Figure 2A](#fig2){ref-type="fig"}: the authors don\'t address concerns about the quality of the Myc-GFP staining or show higher mag images.

5\) In minor point 10 about [Figure 2D](#fig2){ref-type="fig"}: is it not acceptable to run a negative control on a separate gel.

6\) Response to minor point 10, [Figure 3A](#fig3){ref-type="fig"}. Increasing the concentration of until one sees a response is a bit iffy. The explanation is confusing.

7\) Likewise, the response to minor point 10, [Figure 7A&B](#fig7){ref-type="fig"} is unsatisfactory. The difficulties in getting good bands with some proteins and antibodies in Western blots is acknowledged. However, these are really very difficult to see and if the authors ran it 4 times and these are the best looking bands, the accuracy and reliability of these bands are questionable. Readers should not have to squint to tell whether or not there is a band present. The images are very grainy and pixelated.

8\) The response to Major point 9 is "hand-wavy"\... Are the authors trying to say that, yes, they think Vax1 actions are both chemotrophic and chemotropic, or are they undecided? As it currently reads, these statements are weak.

Reviewer 2:

Overall, I think the manuscript is much improved, particularly with respect to grammar and inclusion of appropriate references and added discussion points. The authors have addressed most of the concerns to an acceptable level, and I would support the acceptance of the paper, pending addressing the following points:

Regarding substantive concerns point 2: Although NrCAM and VegfA are expressed in the Vax1-/- chiasm, the morphology of the chiasm is clearly abnormal (Figure A.B and Supplemental Figure 1). In the text, the authors state: "The development of these OC-forming cells was normal in Vax1-deficient (Vax1-/-) mice ([@bib2]) (Figure 9 1A,B; bottom rows), suggesting that the impairment in OC development in Vax1-deficient mice is not caused by the lack of OC-forming vHT cells but rather by a loss of RGC attractant molecules in these cells ". It would be more accurate to state: "Although the morphology of the chiasm is abnormal in Vax1-/- deficient mice, the OC-forming cells and several chiasm localized cues (NrCAM, VegfA) are present."

Also regarding substantive concerns point 2, with respect to the point about HSPGs functioning as co-receptors for other secreted proteins, I think the authors missed the reviewers\' point. If I understand correctly, they were asked to consider whether Vax1/HSPGs co-localize with known cell surface receptors that may mediate internalization of Vax1. In addition, the co-localization of Vax1 and Sdc3 in RGC axons in tissue sections is pretty dirty and the co-localization isn\'t very convincing. Have the authors tried this in cultured RGCs? This might improve the quality of the images.

Regarding substantive concerns point 5: Despite the fact that Vax2 is not secreted, the ability of recombinant Vax2 to be internalized and induce axonal growth strengthens the findings of the paper. These data should be included in the manuscript as a supplemental figure, at the least.

Regarding substantive concerns point 8: While the authors nicely showed that Vax1 and Slit compete with one another for binding to HSPGs, they did not show whether addition of Slit blocks Vax1\'s ability to induce translation in axons. Did the authors do this experiment?

Regarding substantive concerns point 9: The authors should include the data showing that the Vax1 antibody blocks the function of Vax1 secreted from Cos7 cells as supplemental data.

Regarding minor concern 7: If this is the best image for IP experiments, perhaps the authors could complement the experiments by using overexpression of tagged constructs for Sdc2, Sdc3, Pax2 and Glp1 or by performing the reverse IP if antibodies are available.

In general, the proposed model of Vax1 action in RGC axons is still a bit confusing. Does it primarily function as a promoter of axonal growth via increased translation, or by competing with Slit binding to HSPGs? While these need not be mutually exclusive, I\'m still a little unclear as to what the Slit/Robo data adds to the model, since Slit doesn\'t function as a general inhibitor of growth, but rather functions as a repulsive cue from the surrounding tissue.

10.7554/eLife.02671.030

Author response

*1) The references to other studies are deficient (missing or improper citation/interpretation) and the text should be edited for proper English usage. For example, the authors should cite papers regarding the idea that HSPGs are involved in axon guidance, and particularly at the optic chiasm, since this is not a new concept. For example:* [@bib8]*, J Comp Neurol 436: 236;* [@bib35]*, J Neurosci.26:6911; Conway et al., 2011, J Neurosci 31: 1955; Wilson and Stoeckli, 2013, Neuron 79:478; Sánchez-Arrones et al., 2013, J Neurosci 33:8596; Fabre et al., 2010, J Neurosci 30:266 and Yam and Charron, Curr Op Neurobiol 2013)*.

The manuscript was streamlined, reflecting revisions, and edited by multiple native-English speakers, including a professional scientific editor. As suggested by the reviewers, we have also added references relating to the functions of HSPGs as co-receptors for secreted.

*2) Although the authors show that the chiasm appears normal by RC2 staining, they should confirm that the expression of known chiasm localized cues (Vegf, ephrinB1, NrCAM) is normal*.

We examined expression of two vHT RGC attractive cues, *Vegfa* and NrCAM, by *in situ* hybridization and immunostaining, respectively. The results indicated that these chiasm cues are still expressed in E14.5 *Vax1-ko* mouse embryonic ventral diencephalon ([Figure 1--figure supplement 1](#fig1s1){ref-type="fig"}). These are even expanded more dorsally, suggesting that defective midline access of *Vax1-ko* mouse RGC axons was not resulted from the loss of these attractive chiasm cues.

*Similarly, there is no information on localization of HSPGs on RGCs nor is there any proposal/analysis on the fate of HSPGs after Vax1 binds: are they also internalized? If not, are they cleaved once bound to Vax1? These points should be discussed*.

We investigated the distribution of Vax1 and Sdc3 in E14.5 mouse retinas by co-immunostaining. As shown in [Figure 7](#fig7){ref-type="fig"} and [Figure 7--figure supplement 2](#fig7s2){ref-type="fig"}, Vax1 and Sdc3 are co-localized in RGC axons, whereas these co-localized Vax1 signals disappeared after treating retinal sections with heparinase I. These results suggest that Vax1 interacts with Sdc3 in a HS-dependent manner at the cell surface, but is unlikely internalized by Sdc3-mediated endocytosis, which can protect Vax1-HS interaction from heparinase. We were also not able to detect any cleavage of Sdc2 or Vax1 in transfected cells. We provide the results for the reviewers' inspection only. Our overall hypothetical model is that HSPGs capture secreted Vax1 and release it to the plasma membrane for further cytoplasmic penetration.

*A large number of HSPG binding proteins have been identified (e.g. FGF2, slit2, Semas, ephrins, syndecans, glypicans, etc). For all these cues HSPGs function as co-receptors for a transmembrane spanning signaling receptor. The authors should discuss this possibility and whether there is data for co-localization of these on RGCs*.

We discussed possible roles of HSPGs as co-receptors for netrin, Shh, and Slit during axonal projection of spinal commissural neurons and RGCs (please see the first paragraph of Discussion). We did not check the co-localization of these cues on RGCs. We have also not found any studies reporting co-localization of these cues on RGC axons, although previous results suggest that HSPGs are required for the actions of netrin and Slit on RGC axons ([@bib18]; [@bib31]).

*3) The explants tested were taken from dorsal retina, at E13, when a few cells project ipsilaterally but ultimately disappear. The ventrotemporal retina gives rise to the permanent ipsilateral component after E14. Have the authors analyzed expression of syndecan or glypican in the "ipsi" retina and how Vax1-HSPG interactions underlie ipsi axon midline avoidance? This could be addressed by comparing ventrotemporal versus dorsotemporal retina*.

We examined the distribution of Sdc3 in E14.5 retinas, and found no region-specific enrichment of Sdc3 in the nasal-temporal (N/T) axis (Sdc3 images in [Figure 7--figure supplement 2](#fig7s2){ref-type="fig"}). These results are consistent with a previous report showing a uniform distribution of HSPGs in RGCs along the N/T axis ([@bib8]).

We also tested axonal responses of retinal quadrants to Vax1. We provide the results for the reviewers' inspection. The results suggest that ventral retinal axons respond to Vax1 as efficiently as those from the dorsal retinal explants. These results also show that V/T retinal axons express Sdc3 and project as efficiently as those from the dorsal retinal explants upon incubating with Vax1.

Therefore, as we propose in our model ([Figure 9C](#fig9){ref-type="fig"}), Vax1 supports the projection of RGC axons toward the vHT midline regardless of their original positions in the retina. In the vHT midline, EphB1-expressing V/T RGC axons are repelled by ephrinB2-expressing radial glia while the remaining RGC axons continue growing in the contralateral direction.

4\) The authors propose that vax1 overrides Robo/slit repulsion. Is slit repulsion of cultured RGC axons reduced (blocked) in the presence of recombinant vax1?

Yes. Slit and Vax1 competitively inhibit each other's effects as well as their binding to RGC axons (please see revised [Figure 9--figure supplement 1](#fig9s1){ref-type="fig"}).

*Slits are thought to inhibit RGC axons from straying (defasciculating) from the main bundles at the chiasm, in an "inhibition-surround" mechanism, not as an inhibitory molecule at the crossing point (see Erskine et al., J Neurosci 2000, 20:4975;* [@bib34] *Neuron 33:219)*.

As the reviewers indicate, Slit-Robo signaling inhibits RGC axons from exiting the optic track and projecting toward ectopic sites, such as the POA and contralateral OS ([@bib13]; [@bib34]). This suggests that the role of Slit-Robo signaling in RGC axons is related to reducing the dynamics of the RGC axon growth cone rather than specifically enhancing fasciculation, which is still normal in the OS of *Slit1/2-ko* mice (please see [Figure 3](#fig3){ref-type="fig"} of [@bib34], Neuron 33: 219).

*The authors placed Vax-1-containing cells in the third ventricle above the chiasm in an isolated prep, showing that growth was enhanced, and application of Fc-Robo3 also enhanced RGC axon growth (together growth was further enhanced). While this experiment argues for Slit involvement in this preparation, it cannot relate to guidance in vivo because Robo3 is not expressed in the mouse retina (see above references and Thompson et al., 2006, J Neurosci 26:8092). Further, there should be axon extension in the control preparation in* [*Figure 9A*](#fig9){ref-type="fig"}.

As the reviewers' indicated, Robo3 is not expressed in mouse RGCs, where Robo1 and Robo2 are consistently expressed ([@bib13]). In addition, Robo3-Fc alone was not effective in restoring RGC axon growth in *Vax1-ko* mouse embryos (original [Figure 9](#fig9){ref-type="fig"}).

In the revised manuscript, we therefore replaced the original results with those using Robo1-Fc. As shown in revised [Figure 9B](#fig9){ref-type="fig"}, implanted Robo1-Fc induced RGC axon regrowth in *Vax1-ko* mouse brains and it further facilitated the effects of co-implanted Vax1.

*Finally, the model posed in* [*Figure 9*](#fig9){ref-type="fig"} *is misleading: how would the Vax1-HSPG interaction act on Slit inhibition leading to action of molecules important for contralateral crossing (e.g., VEGF164, NrCAM, and Semaphorin6D, latter, erroneously indicated for ipsilateral growth)?*

We modified our model (revised [Figure 9C](#fig9){ref-type="fig"}) regarding Vax1 and Slit competition for HSPGs in RGC axons and antagonistic regulation of local translation. Accordingly, in this competition, vHT-enriched Vax1 displaces Slit, which is bound to HSPGs in RGC axons at the lateral diencephalon, and promotes further growth toward the midline where RGC axons meet pathway determinants (e.g., VEGF164, NrCAM, Semaphorin6D, and ephrinB2).

*5) The authors show that in contrast to Vax1, Vax2 is not secreted and does not bind to HSPGs (*[*Figure 2C*](#fig2){ref-type="fig"}*,* [*Figure 7--figure supplement 1B*](#fig7s1){ref-type="fig"}*). This is somewhat surprising, since the domains that regulate secretion of homeodomain transcription factors are typically within the homeodomain region, which is highly conserved between Vax1 and Vax2. Have the authors attempted to identify the specific domains required for secretion and HSPG binding that differ between Vax1 and Vax2?*

According to our unpublished results, only about 40% of homeodomain transcription factors can be secreted at least in one cell type (*Lee et al., manuscript in preparation*). It suggests that secretion of homeodomain proteins is not solely dependent of homeodomain but rely on their three-dimensional structures. Therefore, in COS7 cells, Vax2 might fail to form a three-dimensional structure that can be recognized by secretion machineries that have not been identified yet.

We previously showed that Vax2 can be localized to the cytoplasm of the developing mouse retina ([@bib22]). This cytoplasmic retention of Vax2 is mediated by phosphorylation at S170, which is absent in Vax1. However, replacing of this phosphorylation site by alanine (S170A) or aspartate (S170D) was failed to induce secretion of the Vax2 proteins (data not shown). It suggests that the phosphorylation-induced cytoplasmic retention of Vax2 is unlikely related with secretion.

*The authors should test whether the addition of exogenous Vax2 can bind to RGCs and promote their outgrowth using assays like those used in* [*Figure 3*](#fig3){ref-type="fig"}.

Bacterial-expressed recombinant Vax2 was able to induce RGC axon growth after penetration. We provide the results for reviewers' inspection only. This suggests that Vax2, which shares an identical cell-penetration sequence with Vax1, is functionally equivalent to Vax1 *in vitro* but is simply not secreted from COS7 cells.

6\) Immuno-EM studies show that vax1 is localized to the axonal surface of RGCs and also found in endocytosed vesicles. To participate in local translation, vax1 likely needs to be in the cytoplasm not inside vesicles?

In the revised manuscript, we provide additional iTEM images showing cytoplasmic Vax1 (please see [Figure 4--figure supplement 2](#fig4s2){ref-type="fig"}).

*7) In the co-culture assays in* [*Figure 1C-D*](#fig1){ref-type="fig"}*, WT retinal explants cultured with Vax1-/- vHT not only shows no attraction, but appears to show active repulsion. This may be due to the secretion of Slit from the explants, which should be tested by examining whether addition of Robo-Fc (similar to* [*Figure 9A*](#fig9){ref-type="fig"}*) inhibits this repulsion*.

As recommended by the reviewers, we tested the effects of Robo1-Fc on RGC axon growth from retinal explants co-cultured with vHT explants. We provide the results for reviewers' inspection. We found that Robo1-Fc treatment stimulated RGC axonal projection, not only toward *Vax1-ko* vHTs but also in other directions. Therefore, consistent with the reviewers' hypothesis, Slit from the hypothalamic explants repels RGC axons more efficiently in the absence of Vax1.

*With respect to Vax localization and uptake,* [*Figure 4C and D*](#fig4){ref-type="fig"} *shows immunostaining for Vax1 protein on axons and in D in the immune-EM figures, only on the axon surface; this is puzzling as the authors\' model is that Vax1 is internalized and thus one would expect Vax1 to be in the cytoplasm of the cell -- axon or cell body*.

Although a majority of Vax1 bound to the RGC membrane, a significant amount of Vax1 protein was also detectable in the RGC cytoplasm. This cytoplasmic Vax1 protein might be sufficient to exert axon growth-stimulatory effects. In the revised manuscript, we provide additional iTEM images showing cytoplasmic Vax1 (please see images in [Figure 4--figure supplement 2](#fig4s2){ref-type="fig"}).

*8) In* [*Figure 9--figure supplement 1*](#fig9s1){ref-type="fig"}*, the authors show that Vax1 and Slit are mutually antagonistic with respect to axon outgrowth. In the images (S9C), it appears that the addition of Slit blocks Vax1 localization in the axons to some extent. This should be examined in biochemical assays by assessing how the presence of Slit or Vax1 affects the other\'s binding to HSPGs (similar to assays in* [*Figure 7--figure supplement 1A*](#fig7s1){ref-type="fig"}*). Alternatively, it would be informative to know whether addition of Slit inhibits Vax1 induction of axonal translation (*[*Figure 8B*](#fig8){ref-type="fig"}*)*.

To address the competition for HSPG binding between Vax1 and Slit, we added Vax1 and Slit2 proteins under the same conditions tested in [Figure 9 -- figure supplement 1A](#fig9s1){ref-type="fig"}. The results indicated that Vax1 and Slit2 compete for binding to RGC axons ([Figure 9--figure supplement 1C](#fig9s1){ref-type="fig"}). These results therefore suggest that Vax1 and Slit proteins compete for binding to the sugar chain in the extracellular domain of HSPGs. However, a possible antagonism between Vax1 and Robo signaling in enhancing the translation of specific target mRNAs cannot be excluded at this point. Therefore, we propose a model in which Vax1 antagonizes Slit-Robo signaling not only at the level of ligand accumulation but also at the level of intracellular signaling ([Figure 9C](#fig9){ref-type="fig"}).

*9) It is not clear whether soluble vax1 primarily exerts its function as a growth promoting factor (chemotrophic, i.e.* [*Figure 5*](#fig5){ref-type="fig"}*) or steering function (chemotropic, i.e.* [*Figure 1*](#fig1){ref-type="fig"}*) or both?*

Vax1 can also play roles as a steering factor in certain context, which Vax1 is expressed in a specific region. In mouse optic pathway, Vax1 is expressed in OS as well as vHT ([@bib2]; [@bib15]). It makes RGC axons be consistently exposed to Vax1 until it reaches to optic tract. In addition, Vax1 not only works in RGC axon terminal, but it is also present in axon shaft to promote axon growth ([Figure 8](#fig8){ref-type="fig"}). Therefore, we propose Vax1 is an axon growth factor in general.

Can the effects of vax1 secreted from COS7 cells be blocked in the presence of the anti-vax1 serum?

We provide results showing that anti-Vax1 antibody sequestered secreted Vax1 from COS7 cells and blocked the transfer of Vax1 into retinal axons. We provide the results for reviewers' inspection.

*10) Blocking of translation with anisomycin may affect neurite outgrowth in a vax1-independent manner. Additional controls are needed to show that in the presence of a growth promoting cue (other than vax1) blocking of translation with anisomycin does not influence outgrowth rate*.

As the reviewers indicated, anisomycin does not specifically affect Vax1; it also inhibits global translation, which is essential for RGC axon growth induced by other cues (Lin &Holt, 2007). Accordingly, since results obtained with anisomycin may be misleading, we eliminated them from the revised manuscript.

\[Editors' note: the reviewers had the following concerns after re-review, which were addressed before acceptance.\]

*We are very sorry to report that, after a second round of review, the changes you made were not deemed to sufficient to render your paper acceptable for publication in eLife at this point. We hope that the detailed comments of the reviewers will help you in improving the paper*.

As you can find from the comments of our reviewers, they mostly indicate an unclear explanation about the function of secreted Vax1 between an axon growth promoting factor and a steering factor. I admit that we might not have understood the reviewers' questions fully and answered insufficiently in our rebuttal. Now, we understand it exactly and can answer clearly that "Vax1 is a novel axon growth promoting factor, which works in RGC axoplasm to activate local protein synthesis, than a steering factor that mainly acts on specific receptors to trigger on intracellular signaling cascades." This will also be further clarified in the text and by drawing a separate model diagram with details as reviewer \#1 proposes.

Reviewer 1:*The authors have addressed the reviewers\' comments, performing additional experiments and presenting new micrographs and other data. Nonetheless, there are still some amendments needed to clarify the model and data*.

*1) The reader must still work very hard in understanding how Vax acts to enhance axon growth*.

*a) One problem is that the authors "tell the story" in different ways, sometimes completely and in other places, leaving out one of the elements*.

In this paper, we propose Vax1 as a novel RGC axon growth factor that binds to HSPGs and enters into RGC axoplasm to trigger local translation. We believe this message is consistent throughout the paper, although it is expressed with different emphases in each paragraph. However, we modified or eliminated expressions that could make our readers difficult to understand the conclusion correctly.

*In the rebuttal: "Our overall hypothetical model is that HSPGs capture secreted Vax1 and release it to the plasma membrane for further cytoplasmic penetration*.*"*

This expression emphasizes roles of HSPGs that capture Vax1 for subsequent cell penetration but do not induce intracellular signaling cascades or endocytosis of Vax1. This is not a key part of our answer to the reviewer's question that asks a potential endocytosis or cleavage of HSPG-interacting Vax1. We eliminated this sentence from the rebuttal.

*"This unconventional axon growth factor also utilizes HSPGs for anchoring to RGC axons and antagonizes Slit effects on RGC axon binding and growth (*[*Figure 9--figure supplement 1*](#fig9s1){ref-type="fig"}*)*.*"*

This sentence is a part of a paragraph that compares an orchestrated RGC axon growth to that of commissural axons of spinal cord. It describes the reciprocal antagonism between Vax1 and Slit in RGC axons as an analogous event of netrin (or Shh) and Slit in spinal commissural axons. In following this sentence, however, we emphasize the main activity of Vax1 in RGC axon as that 'In addition, imported Vax1 promotes RGC axon growth by stimulating local protein synthesis ([Figure 8](#fig8){ref-type="fig"})'. We rewrote the paragraph to avoid the misinterpretation that Vax1 mainly interferes with Slit-Robo interaction to support RGC axon growth.

*In the rebuttal, second paragraph: "We modified our model (revised* [*Figure 9C*](#fig9){ref-type="fig"}*) regarding Vax1 and Slit competition for HSPGs in RGC \... in this competition, vHT-enriched Vax1 displaces Slit, which is bound to HSPGs in RGC axons at the lateral diencephalon, and promotes further growth toward the midline where RGC axons meet pathway determinants (e.g., VEGF164", etc)*.

This is the part of our answer to the reviewer's question related to the effects of Vax1 on contralateral pathway determination cues (e.g., VEGF164, NrCAM, and Semaphorin6D). We added to this sentence to emphasize that Vax1 does not influence to the expression of these pathway determination cues (please see [Figure 1--figure supplement 1](#fig1s1){ref-type="fig"}) but promotes RGC axons to grow to the midline where these cues are expressed. However, the expression like '*vHT-enriched Vax1 displaces Slit...*' might lead to misunderstanding that main activity of Vax1 is competing with Slit. Thus, we rewrote our rebuttal by eliminating the part expressed improperly.

*b) The all-important schema graphically illustrating the steps, in* [*Figure 9*](#fig9){ref-type="fig"}*, does not clearly illustrate what the authors intend to describe. From the graphic, one cannot intuit the process of Vax attachment to HSPGs on RGC surface, then enhancement of growth during midline crossing*.

We presented this simplified model owing to limited space as a sub-figure, i.e. [Figure 9D](#fig9){ref-type="fig"}. We present a detailed diagram in a separate figure, i.e. [Figure 10](#fig10){ref-type="fig"}, reflecting the reviewer's requests in following.

The various interactions might be broken into steps (attachment of Vax to HSPGs, then internalization, followed by retrograde transport to the cell body and/or action locally in the growth cone, finally axon extension)?

*The growth cone should be enlarged, and perhaps use a different icon for the guidance molecules*.

*Sema6D is not a repellant for ipsilateral axons; it belongs with NrCAM on the contralateral axons*.

We apologize for omitting Sema6D in the contralateral cues. Sema6D is indeed a context-dependent cue for RGC axons rather than simple an attractive or repulsive cue as Erskine *et al.* (2013) showed. It repels RGC axons in the absence of NrCAM and Plexin A1. To avoid confusion, we simplified the attractive cues as NrCAM and VEGF164 in our revised model diagram ([Figure 10D](#fig10){ref-type="fig"}).

*2) In the rebuttal, major point 7: The co-culture assays with knockout vHT and Robo1-Fc should be included in the manuscript; these are important data and should not be hidden only for reviewers\' inspection*.

Following the reviewer's suggestion, we included this figure in the paper. The reason that we provided this for reviewers' inspection only was not for hiding but for making the paper compact. The original paper already had a large body with 9 figures, 9 figure supplements, and 2 video files. We were afraid that our readers would be overwhelmed by the large amount of data. In the revised paper, we provide all "reviewers' inspection only" figures as figure supplements.

*3) Response to minor point 7 is a little dismissive and unsatisfactory. The DiI labeling in the images of cryosectioned DiI is so fuzzy/overexposed/difficult to see clearly, that they would be better off just using the cytoarchitecture to determine the location of the RGC axon bundle. As is, the DiI quality distracts from the overall point of the figure. If the immunostaining is more important for them to show, as they indicate, they should focus on that and orient things based on cytoarchitecture, which should be sufficient to locate the axon bundles, and just leave out the DiI altogether*.

We removed DiI fluorescence images from dark field images in the figures as the reviewer suggests. We also redraw a schematic diagram of slab experiment in [Figure 4D](#fig4){ref-type="fig"} (please see a drawing in top row).

*4) In minor point 10 re:* [*Figure 2A*](#fig2){ref-type="fig"}*: the authors don\'t address concerns about the quality of the Myc-GFP staining or show higher mag images*.

We did not use Myc-GFP for control but use 3X-Myc tag in this figure. We have already provided a negative control for anti-Myc antibody on top row (Mock).

*5) In minor point 10 about* [*Figure 2D*](#fig2){ref-type="fig"}*: is it not acceptable to run a negative control on a separate gel*.

We replaced these with new Western blot bands shown in a same gel.

*6) Response to minor point 10,* [*Figure 3A*](#fig3){ref-type="fig"}*. Increasing the concentration of until one sees a response is a bit iffy. The explanation is confusing*.

We explained more clearly in the revised rebuttal. We also provide a video recorded retinal axons treated with 6X-His-FITC peptide at same weight of Vax1-His-FITC protein (please see [Video 3](#video3){ref-type="other"}).

*7) Likewise, the response to minor point 10,* [*Figure 7A&B*](#fig7){ref-type="fig"} *is unsatisfactory. The difficulties in getting good bands with some proteins and antibodies in Western blots is acknowledged. However, these are really very difficult to see and if the authors ran it 4 times and these are the best looking bands, the accuracy and reliability of these bands are questionable. Readers should not have to squint to tell whether or not there is a band present. The images are very grainy and pixelated*.

We repeated the experiments with rabbit anti-Glp1 and anti-Sdc3 antibodies from different company sources, and replaced those with new results with better qualities (please see revised [Figure 7B](#fig7){ref-type="fig"}).

*8) The response to Major point 9 is "hand-wavy"\... Are the authors trying to say that, yes, they think Vax1 actions are both chemotrophic and chemotropic, or are they undecided? As it currently reads, these statements are weak*.

Although we believed Vax1 is mainly a chemotrophic factor, which stimulates RGC axon growth in a non-direction selective manner, we could not rule out a possible chemotropic activity in a certain condition such that Vax1 can bind to unidentified receptors that turn on intracellular signal cascades. However, our current results ([Figure 8](#fig8){ref-type="fig"}) decline the latter chemotropic activity of Vax1. We therefore answered more clearly by changing our rebuttal (please see our revised rebuttal to Substantive concern \#9).

Reviewer 2: *Overall, I think the manuscript is much improved, particularly with respect to grammar and inclusion of appropriate references and added discussion points. The authors have addressed most of the concerns to an acceptable level, and I would support the acceptance of the paper, pending addressing the following points:*

*Regarding substantive concerns point 2: Although NrCAM and VegfA are expressed in the Vax1-/- chiasm, the morphology of the chiasm is clearly abnormal (Figure A.B and Supplemental Figure 1). In the text, the authors state: "The development of these OC-forming cells was normal in Vax1-deficient (Vax1-/-) mice (*[@bib2]*) (Figure 9 1A,B; bottom rows), suggesting that the impairment in OC development in Vax1-deficient mice is not caused by the lack of OC-forming vHT cells but rather by a loss of RGC attractant molecules in these cells ". It would be more accurate to state: "Although the morphology of the chiasm is abnormal in Vax1-/- deficient mice, the OC-forming cells and several chiasm localized cues (NrCAM, VegfA) are present*.*"*

We appreciate the reviewer's suggestion and changed the expression in the text.

*Also regarding substantive concerns point 2, with respect to the point about HSPGs functioning as co-receptors for other secreted proteins, I think the authors missed the reviewers\' point. If I understand correctly, they were asked to consider whether Vax1/HSPGs co-localize with known cell surface receptors that may mediate internalization of Vax1. In addition, the co-localization of Vax1 and Sdc3 in RGC axons in tissue sections is pretty dirty and the co-localization isn\'t very convincing. Have the authors tried this in cultured RGCs? This might improve the quality of the images*.

We replaced these with co-staining images with Vax1/NF160/Sdc3 in [Figure 7D](#fig7){ref-type="fig"}.

*Regarding substantive concerns point 5: Despite the fact that Vax2 is not secreted, the ability of recombinant Vax2 to be internalized and induce axonal growth strengthens the findings of the paper. These data should be included in the manuscript as a supplemental figure, at the least*.

We included the results as [Figure 3--figure supplement 3](#fig3s3){ref-type="fig"}.

Regarding substantive concerns point 8: While the authors nicely showed that Vax1 and Slit compete with one another for binding to HSPGs, they did not show whether addition of Slit blocks Vax1\'s ability to induce translation in axons. Did the authors do this experiment?

We have done the experiments but failed to observe the inhibition of translation (data not shown). It might be related with Slit-Robo also induces local translational for RGC axon growth cone repulsion.

*Regarding substantive concerns point 9: The authors should include the data showing that the Vax1 antibody blocks the function of Vax1 secreted from Cos7 cells as supplemental data*.

We included the results as [Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}.

*Regarding minor concern 7: If this is the best image for IP experiments, perhaps the authors could complement the experiments by using overexpression of tagged constructs for Sdc2, Sdc3, Pax2 and Glp1 or by performing the reverse IP if antibodies are available*.

We replaced these with new results with better qualities (please see revised [Figure 7B](#fig7){ref-type="fig"}).

*In general, the proposed model of Vax1 action in RGC axons is still a bit confusing. Does it primarily function as a promoter of axonal growth via increased translation, or by competing with Slit binding to HSPGs? While these need not be mutually exclusive, I\'m still a little unclear as to what the Slit/Robo data adds to the model, since Slit doesn\'t function as a general inhibitor of growth, but rather functions as a repulsive cue from the surrounding tissue*.

We apologize to leave this part still unclear. This can be clarified by removing unnecessary sentences that we had added in the rebuttal as well as in the manuscript. As we answered to reviewer \#1, the main activity of Vax1 for RGC axon growth is a promoter of axonal growth via local protein synthesis than HSPG binding. We also redrew a hypothetical model diagram by explaining HSPGs binding of Vax1, cell penetration, and stimulating local translation in detail (please see [Figure 10](#fig10){ref-type="fig"}).
